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Summary 
 
In patients with chronic myeloid leukemia (CML), the occurrence of point 
mutations within the BCR-ABL1 tyrosine kinase (TK) domain is currently the 
most common mechanism of resistance to therapy with TK inhibitors. To date a 
variety of different techniques to the detection of relevant point mutations is 
available. This mainly includes methods displaying a limited level of sensitivity 
e.g. bidirectional sequencing, the standard method of choice, providing a 
sensitivity of ~ 20%. However, the presence of cells carrying resistant mutations 
does not necessarily imply imminent disease progression. Mutation analysis by 
qualitative methods may therefore be insufficient to reliably identify clinically 
relevant resistant clones. To address this problem, an application permitting the 
detection of point mutated subclones of clinically relevant size and the 
additional option for quantitative analysis might be of great benefit. Thus the aim 
was to establish a technique combining both requirements. The newly 
developed LD-PCR relies on specific probe hybridization to mutant and wild-
type sequences followed by ligation-dependent competitive PCR. Amplicons are 
detected and quantified via fluorescence-based capillary electrophoresis.  
Assays have been established for 21 common BCR-ABL1 TK point mutations 
including M244V, L248V, V299L-C/T, G250E, Q252H-C/T, Y253F, Y253H, 
E255K, T315A, T315I, F317C, F317I, F317L-A/G, F317V, M351T, F359V, 
H396P and H396R. Moreover the technique is adaptive to any kind of point 
mutation as shown for the detection of V617F point mutation within the JAK2 
gene, relevant for several myeloproliferative disorders. The LD-PCR assays 
display a detection limit of 1-5% and permit quantitative monitoring of mutant 
clones during the course of treatment.  The applicability in CML patients 
undergoing treatment with TK inhibitors and the existence of kinetic proliferation 
of mutated cells clones could be demonstrated. Assessment of the size and 
proliferation kinetics of clones carrying specific mutations could therefore be 
instrumental in the clinical surveillance and therapeutic management of CML 
patients. 
  6 
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Zusammenfassung 
 
Bei Patienten mit chronisch myeloischer Leukämie (CML) ist das Auftreten von 
Punktmutationen in der BCR-ABL1 Tyrosinkinasedomäne (TK)  die am 
häufigsten beschriebene Ursache für Resistenzen gegen Tyrosinkinase-
Inhibitoren (TKI). Für die Detektion von Punktmutationen ist eine Auswahl an 
Methoden verfügbar. Diese sind jedoch oft wenig sensitiv, wie zum Beispiel die 
Standardmethode der bidirektionalen Sequenzierung, mit einer Sensitivität von 
circa 20%. Das Auftreten von TKI resistenten Zellklonen muss jedoch nicht 
notwendigerweise mit einer bevorstehenden Progression der Krankheit 
assoziiert sein. Die Analyse von mutanten Zellklonen mit qualitativen Methoden 
könnte daher unzureichend sein, um klinisch relevante Klone zu identifizieren. 
Um diese Problematik bearbeiten zu können, wäre eine Methode von Vorteil, 
die die Detektion von Punktmutationen in einem klinisch relevanten Bereich mit 
der Möglichkeit zur Quantifizierung vereint. Solch eine Methode galt es zu 
entwickeln. Die neu etablierte LD-PCR Methode basiert auf der Hybridisierung 
spezifischer Sonden an die Wildtyp (WT) bzw. mutierte Sequenz gefolgt von 
einer ligations-abhängigen kompetitiven PCR. Die generierten Amplikons 
werden mittels Kapillarelektrophorese detektiert und quantifiziert. LD-PCR 
Assays wurden für folgende 21 häufig vorkommenden BCR-ABL1 TK  
Punktmutationen etabliert: M244V, L248V, V299L-C/T, G250E, Q252H-C/T, 
Y253F, Y253H, E255K, T315A, T315I, F317C, F317I, F317L-A/G, F317V, 
M351T, F359V, H396P and H396R. Das Konzept der LD-PCR ist auf jegliche 
Punktmutation umlegbar, wie am Beispiel der Punktmutation V617V im JAK2 
Gen, die bei myeloproliferativen Erkrankungen prognostisch bedeutend ist, 
gezeigt werden konnte. Die LD-PCR Assays haben eine Sensitivität von 1-5% 
und ermöglichen eine quantitative Überwachung während des 
Behandlungsverlaufs.  
Die Anwendbarkeit dieser Methode bei CML Patienten unter TKI Behandlung 
konnte ebenso gezeigt werden wie das Vorhandensein einer 
Proliferationskinetik mutierter Zellklone. Die Dokumentation der Größe und der 
Expansion eines mutierten Zellklons könnte die Vorhersage einer 
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bevorstehenden Resistenz ermöglichen und bei der klinischen Überwachung 
sowie bei der Therapiesteuerung von CML Patienten hilfreich sein. 
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1 Introduction 
 
1.1 Chronic myeloid leukemia (CML) 
 
1.1.1 CML- Clinical features 
 
Chronic myeloid leukemia is a clonal myeloproliferative disorder most 
commonly occurring in middle-aged and elderly patients with an incidence of 
one or two cases per 100 000 people every year [1]. Untreated, the disease 
proceeds in three phases: chronic phase (CP), accelerated phase (AP) and, 
finally, blast crisis (BC). Clinical features of chronic phase CML are often 
inconspicuous and most patients show only mild symptoms e.g. elevated white 
blood cell count, malaise, low-grade fever, anemia, thrombocytopenia and 
increased susceptibility to infections. At diagnosis, about 85% of all patients are 
in chronic phase CML and the diagnosis is often based on routine blood tests 
[2,3]. Regarded in detail, granulocytosis occurs and, additionally, is associated 
with a typical left shift of granulopoiesis [1] including less than 10% blast cells in 
bone marrow and blood [4]. Depending on the time point of diagnosis and the 
therapy applied, the chronic phase can last several months to several years.  
Progression to accelerated phase is characterized by a blastic transformation 
[3] accompanied by a variety of clinical features, mainly including increasing 
myeloblasts up to ~ 20%, increasing white blood cell count and splenomegaly  
(specified in detail in [5,6].)  
The last stage of CML is represented by a blast crisis which is comparable to a 
phenotype of acute leukemia. Within this phase, leukemic blast cells are 
present ≥ 30% in bone marrow or peripheral blood [3,5,6]. It can express 
lymphoid characteristics in about 1/3 of the cases, whereas 2/3 represent as 
acute myeloblastic or undifferentiated leukemia-like phenotype [3].  
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1.1.2 Molecular characteristics of CML 
 
1.1.2.1 Philadelphia chromosome and rearrangement of BCR and ABL1 gene 
 
CML was the first neoplastic disease associated with a chromosomal 
aberration. This cytogenetic abnormality results from the reciprocal 
translocation t(9;22) (q34;q11) [7] of the long arms of chromosome (Chr.) 9 and 
22. Following translocation, two derivative chromosomes, an extra-long Chr. 9 
and a shortened Chr. 22, the “Philadelphia  (Ph) chromosome”, are formed [8]. 
Latter was discovered by Nowell and Hungerford in 1960 [9].  
On the molecular level, this translocation results in the rearrangement of two 
genes, BCR (breakpoint cluster region) located on Chr. 22 and ABL1 (abelson) 
primarily located on Chr. 9., whereas the disease-relevant fusion gene is 
present on the Philadelphia chromosome, as depicted in Figure 1. 
 
 
 
 
Figure 1 [10] shows physiological chromosome 9 and 22 as well as the extra-long chromosome 
9 and the shortened chromosome 22 (Philadelphia chromosome) present after the reciprocal 
translocation event. 
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The physiological ABL1 gene belongs to the family of nonreceptor tyrosine 
kinases (TKs) [11-13]. TKs transfer phosphate groups from its donor ATP to 
tyrosine residues on specific cellular proteins, which are mainly involved in cell 
proliferation and differentiation [13].  
Cellular functions of the BCR gene are still ambiguous at the moment. However, 
a tyrosine residue at amino acid (AA) position 177 (Tyr 177) plays an important 
role: when phosphorylated in the rearranged BCR-ABL1 gene, it is a critical 
anchor for Grb-2, an important adapter molecule within the RAS pathway 
[13,14], referred to later on.  
The juxtaposition of parts of both genes results in fusion transcripts that encode 
for a constitutively active tyrosine kinase and this mechanism was identified as 
significant in the pathogenesis of CML [15,16]. 
Breakpoints within the ABL1 gene mostly occur in a region of ~ 200 kb between 
exons 1a and 1b. In case of the BCR gene, three prominent breakpoint regions 
are described: Mbcr (major breakpoint cluster region), a region between exons 
e12 and e16, mbcr (minor breakpoint cluster region) between exons e1 and e2 
and µbcr (µ breakpoint cluster region) located downstream of exon 19 [8].  
 
In either case, ABL1 exon 2 (a2) represents the fusion partner for the exon 
acquired from the BCR gene. For major BCR-ABL1, alternative splicing gives 
rise to two fusion transcripts: b2a2 or b3a2, both translated into a fusion protein 
of 210 kDa (p210BCR-ABL1) [17] which is found in the great majority (≥ 95%) of 
CML patients and in about 30% of Ph+ acute lymphoblastic leukemia (ALL) 
cases [18]. The e1a2 transcript is expressed in case of minor BCR-ABL1, 
resulting in a protein of 190 kDa (p190BCR-ABL1) which is present in ~ 70% of Ph+ 
ALL cases but is only infrequently found in CML. A protein of 230 kDa (p230BCR-
ABL1) is encoded by the fusion transcript e19a2 which is associated with chronic 
neutrophilic leukemia, a mild form of CML, but is rarely found in CML and Ph+ 
ALLs. 
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Figure 2 [8] shows the arrangement of exons within the BCR and ABL1 gene as well as the 
respective breakpoint regions described above. The predominantly occurring BCR-ABL1 
rearrangements and resulting BCR-ABL1 protein isoforms are depicted below. 
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1.1.2.2 Functional domains within the BCR-ABL1 protein 
 
As displayed in Figure 3, the rearranged part of the BCR gene is located at the 
N-terminal site of the fusion protein and contributes three important domains: a 
coiled-coil oligomerization domain, which allows constitutive oligomerization and 
promotes constitutive trans-phosphorylation [19]; a serine/theronine kinase 
domain including Tyr 177; and a guanine-nucleotide exchange factor homology 
domain [8,20]. The adjacent domains are part of the ABL1 protein and contain: 
a highly conserved Src-homology-2 (SH2) domain, a tyrosine kinase domain 
(TKD), three prolin-rich domains functioning as binding sites for downstream 
signalling adapter proteins, three nuclear localizations signals (NLS), a DNA-
binding domain, an actin-binding domain and a nuclear export signal (NES) 
[8,20].  
Via its N-terminal oligomerization domain, BCR-ABL1 monomers form an 
antiparallel dimer that stacks to form a tetramer [20,21]. This altered protein 
complex has a significant impact on signal transduction and a dramatic effect on 
the cellular level emerging as CML.    
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Figure 3. [8] (A) The functional domains of the physiological BCR protein include an 
oligomerization domain at the N-terminal end, a serin/theronine (Ser/Thr) kinase domain 
containing the critical Tyr residue at AA position 177, a Rho/GEF domain, a pleckstrin homology 
(PH) domain and a RAS related C3 botulinum toxin substrate (RAC) guanosine triphosphatase-
activating protein domain (GAP). (B) As a result of alternative splicing the ABL1 protein shows 
two alternative exons (1b and 1a) at its N-terminal end. ABL1b is expressed at higher levels and 
contains a covalently linked C14 myristoyl moiety at the N-terminal position in contrast to ABL1a 
[20]. This is followed by an SH3 and SH2 domain and the TK domain (SH1 TK) containing the 
ATP binding site at Y412 and the transautophosphorylation site at Tyr residue 1294 [13]. The 
second part is assembled by three prolin-rich domains (P), three nuclear localization signals 
(NLS), a DNA binding domain (DNA BD), and an actin binding domain (Actin BD) including a 
nuclear export signal (NES). (C) The BCR-ABL1 fusion protein contains parts of the BCR and 
ABL1 protein.  
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1.1.2.3 BCR-ABL1 signal transduction 
 
The chimeric BCR-ABL1 fusion protein represents the origin for a network of 
altered, enhanced or blocked signalling pathways. Many participating/ 
connecting molecules and proteins have been identified so far, however, the full 
signalling network might not be elucidated yet. Within this chapter, the focus will 
be on a limited number of downstream signalling pathways involved.   
 
Oligomerization of BCR-ABL1 proteins is the first important event for the 
formation of tetramers and facilitates transautophosphorylation at Tyr 1294, 
which is followed by phosphorylation of Tyr 177 located within the BCR-derived 
section. The phosphorylated Tyr 177 is an important high-affinity binding site for 
Grb2 (growth receptor-bound protein 2), which recruits and binds SOS (son of 
sevenless). SOS activates RAS (rat sarcoma) and its downstream molecules 
via guanine-nucleotide exchange. This results in the transcription of genes 
contributing to cell proliferation and transformation [22]. Additionally, Grb2 
activates GAB2 (GRB2-associated binding protein 2), which induces a 
constitutive activation of PI3K (phosphatidylinositol 3-kinase)/AKT [20,23].  
 
Alternatively, BCR-ABL1 directed activation of PI3K/AKT appears to occur via 
phosphorylation of CRKL (v-crk avian sarcoma virus CT10 oncogene homolog-
like), the most abundant phosphorylated protein in CML neutrophils [13] and 
subsequently via CBL (Casitas B-linage lymphoma).  
AKT, a downstream target of Pi3K, activates a plethora of target molecules 
promoting cell survival [8] which mainly includes FoxO proteins, Bad (BCL2 
antagonist of cell death) and GSK3ß (glycogensynthase kinase 3ß). 
Unphosphorylated, Bad can bind to anti-apoptotic Bcl-2 family members (Bcl-
xL), replacing Bax, which subsequently can induce permeabilization of the outer 
mitochondria membrane and activates caspases and apoptosis. In contrast, 
phosphorylated Bad is sequestered by 14-3-3 in the cytosol. This prevents the 
release of Bax and thus lowers the induction of apoptosis [8]. 
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Moreover, activated AKT induces increased transcription of MYC and prevents 
the MYC protein from degradation by inhibiting its degrading enzyme GSK3ß 
[20]. 
 
Other important BCR-ABL1 target proteins are HCK and LYN, members of the 
SCR kinase family. Phosphorylated via BCR-ABL1, they recruit STAT5 (signal 
transducer and activation of transcription 5), which enhances cyclin D1 
transcription, leading to cell-cycle progression from G1 to S-phase [20]. While 
anti-apoptotic BCL-X genes are activated by STAT5, an additional player 
ICSBP (interferon consensus sequence binding protein) represses BCL-X 
genes. It is assumed that BCR-ABL1 indirectly inactivates ICSBP transcription 
and thereby contributes to increased survival of myeloid progenitor cells [20].  
 
This summary gives a limited overview of BCR-ABL1 mediated and altered 
signal transduction processes. Finally, the aberrant signalling cascades mainly 
result in proliferation, transformation and survival of the BCR-ABL1 positive 
leukemic cell, altered adhesion, as well as prevention of apoptosis.  
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Figure 4. [8] Part of BCR-ABL1 mediated signalling pathways.  
 
 
 
Figure 5. [20] Part of BCR-ABL1 mediated signalling pathways. 
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1.1.3 CML – evolutional steps 
 
Concerning the issue of CML evolution, many questions are still not answered. 
However, several observations provide the basis for a rational hypothesis 
published by Valent et al. in 2008 [24]. 
Starting at the level of normal hematopoietic stem cells, these cells might be 
subjected to first mutagenic events, giving rise to premalignant subclones 
lacking the BCR-ABL1 rearrangengement. This assumption is based on the 
findings of BCR-ABL1 negative, but clonal populations of leukemic subclones in 
imatinib treated patients with Ph+ CP CML [24-26]. Following hits might 
introduce the reciprocal translocation event in Chr.9 and Chr.22 attended by the 
fusion of BCR and ABL1 genes within the premaligant stem cell.  
It is discussed whether a BCR-ABL1 positive but clinically silent phase of CML 
might follow, since BCR-ABL1 was already detected in apparently healthy 
individuals. Accordingly, besides the presence of BCR-ABL1, additional genetic 
events might be necessary for the transformation to the chronic phase (CP) of 
CML. Within CML CP, the BCR-ABL1 oncoprotein, however, might be the most 
important parameter providing the basis for proliferation and inhibition of 
apoptosis via aberrant signalling, as already discussed.  
In addition to increased expression of BCR-ABL1, progression to blast phase 
via accelerated phase might require further hits. This includes additional 
chromosomal abnormalities e.g. trisomy eight, isochromosome 17 or duplication 
of Ph chromosome; inactivation of tumor suppressor genes e.g. p53 and 
INK4A/ARF; incorrect DNA repair, and genomic instability and arrest of 
differentiation by the impairment of appropriate transcription factors [20].  
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Figure 6 [24] gives an overview of a potential hypothesis for CML evolution. 
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1.1.4 Therapy concepts in CML 
 
Recombinant interferon-α, which mobilizes the immune system against 
leukemic cells was regarded as a standard therapy in CML patients prior to the 
era of tyrosine kinase inhibitors (TKIs). It was shown to be more effective than 
chemotherapy based on busulfan or hydroxyurea [27]. Interferon-α prolonged 
life in patients of all ages, however the occurrence of severe side effects e.g. 
flu-like symptoms, sickness, weight loss and depression were main drawbacks 
in clinical practice [1].  
 
1.1.4.1 Imatinib mesylate 
 
The development and application of small molecule TKIs was first implemented 
in CML. This concept of targeted therapy was successful using a compound 
developed by Novartis Pharmaceuticals: TKI STI571 (imatinib, Gleevec®). The 
drug inhibits three species of tyrosine kinases: ABL1, PDGFR α and β (platelet 
derived growth-factor receptor) and KIT. In case of ABL1 TK, the concept relies 
on the specific binding of imatinib to the ATP-binding pocket of the constitutively 
active TK. Thus the access of ATP is prevented and phosphate residues 
required for the activation of downstream target molecules (substrate) are not 
available.  
 
 
Figure 7. [28] Imatinib - mode of action.  
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The ABL1 kinase three-dimensional structure provides the basis for 
understanding the underlying imatinib mechanism. The TK consists of different 
parts: N-terminal lobe, ATP-binding domain (p-loop), activation loop, catalytic 
loop and C-terminal lobe. Imatinib is designed to bind to the p-loop region, as 
already mentioned, but only in case of an inactive TK conformation (activation 
loop is closed). Moreover it has been shown that binding of an imatinib 
analogue inside ABL1 is only partly superimposable over that of ATP [29]. This 
observation suggests, that imatinib blocks the kinase activity by stabilizing a 
unique inactive conformation of ABL1, rather than directly competing with ATP 
for binding to the active site [29,30]. Overall, imatinib prevents BCR-ABL1 
autophosphorylation, interferes with TK activation and blocks downstream 
signal transduction [31]. 
 
The success of imatinib treatment in newly diagnosed CP CML patients was 
first presented in the Phase III IRIS (International Randomized Study of 
Interferon and STI571) trial [32]. Within this study, imatinib was compared to 
INFα- and cytarabine. Results, in summary, showed that after a median follow 
up of 19 months, imatinib was significantly better than INFα- treatment, with 
rates of complete hematologic responses (CHR) of 95% and 56%, a major 
molecular response (CCgR ≤ 35% Ph+ cells) of 85% and 22% and superior 
results concerning progression-free survival and major molecular response [32]. 
Based on its superior performance and minor side effects, imatinib is regarded 
as the standard first-line therapy today [33]. 
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1.1.4.2 Resistance to imatinib 
 
Resistance to imatinib can be defined based on hematologic, cytogenetic or 
molecular parameters [34,35] and it can occur in primary and secondary 
instance. Patients with primary resistance show a lack of hematologic or 
cytogenetic response to initial imatinib therapy whereas patients with secondary 
resistance lose their initial response during the course of treatment [34].  
 
Several mechanisms responsible for imatinib resistance have been identified 
and described so far:  
 
i) Overexpression of BCR-ABL1 protein is a phenomenon observed in about 
18% of CML patients [29,36] and results from BCR-ABL1 gene amplification. 
The therapeutic dose of imatinib thus fails to inhibit the increased amount of 
BCR-ABL1 protein [37].  
 
ii) Sufficient imatinib plasma levels are essential for a clinical response to 
imatinib. In this regard, drug influx and efflux mechanisms play an important 
role. Overexpression of the MDR1 encoded glycoprotein, an energy dependent 
efflux pump, results in decreased imatinib plasma levels and is described to 
account for imatinib resistance [38]. The same seems to hold true for the drug 
efflux pump BCRP/ABCG2 [37]. The human organic cation transporter-1 (OCT-
1) was described as the influx pump responsible for imatinib transport into the 
cell. Studies performed in pre-therapy CML patients showed that high OCT-1 
activity was associated with an excellent molecular response, independent of 
the imatinib dosage, whereas response of patients with low OCT-1 activity was 
highly dose dependent [39]. 
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iii) Genomic instability associated with clonal evolution and the activation of 
additional transformational pathways present further opportunities for imatinib 
resistance [40]. This is mainly associated with defects of DNA repair 
mechanisms described to contribute to the progression of CML to advanced 
stages [20].  
 
iv) It has been observed, that imatinib is not able to enter all organ sites. Most 
importantly this is described for the central nervous system because the drug 
cannot cross the blood-brain barrier [41,42]  It is assumed that this is 
attributable to the MDR1-mediated efflux of imatinib [43].  
 
v) Point mutations within the BCR-ABL1 TK domain account for the majority of 
imatinib resistant cases. Since this issue represents the theoretical basis for this 
diploma thesis, it will be discussed in detail within the next section. 
 
 
1.1.5 Point mutations within the BCR-ABL1 tyrosine kinase domain 
 
In case of imatinib, resistance is associated with BCR-ABL1 TK point mutations 
in 40-90% of cases, dependent on the CML phase, the methodology of 
detection and the definition of resistance [44]. The substitution of a single base 
can result in the exchange of an affected amino acid (AA). Referring to the 
nomenclature, the first letter indicates the AA within the wildtype (WT) 
sequence, the number shows the affected AA position within the TK domain 
and the second letter indicates the resulting AA within the point mutated 
sequence e.g. for T315I , the threonine residue at AA position 325 changes to 
isoleucine. 
Depending on the position of the exchanged nucleotide, BCR-ABL1 TK point 
mutations can be clustered into four main groups as comprehensively reviewed 
[29,45]; an overview is displayed in Figure 8. 
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Mutations within the imatinib binding site: affected nucleotides are directly 
interacting with imatinib, either via hydrogen bonds, as in case of T315, or via 
Van der Waals´ interactions as described for V289, T315 and F317. T315I is 
considered as the most important point mutation since the AA occurs in the so 
called, “gatekeeper” position [45]. If T315 is mutated to isoleucine, an important 
hydrogen bond is lost, preventing the interaction of BCR-ABL1 with imatinib 
[46]. Additionally, the isoleucine chain is bulkier and sterically hinders imatinib 
binding [45]. This results in complete insensitivity to imatinib as well as to 
second generation TK inhibitors. Cortes et al. [47] showed that about 15% of 
ABL1 TK point mutations associated with imatinib failure originate from T315I. 
 
Mutations within the ATP-binding loop (P-loop, AA 248-255 of ABL1 TK domain 
[48]): G250E, Y253F, Y253H, E255K and E255V are examples for point 
mutations described within this region and they are described to be associated 
with higher levels of resistance to imatinib [30,40,49]. Moreover, it is discussed 
that p-loop mutations are associated with a poorer prognosis [50], however this 
is still not entirely clear at the moment [51]. 
 
Mutations within the activation loop (AA 381-402): prevent the kinase from 
adopting the inactive conformation to which imatinib can bind [20]. L387M, 
H396R and H396P are described to show impaired imatinib sensitivity [49].  
 
Mutations outside from the imatinib binding site: include changes within the 
catalytic domain (AA 350-363) e.g. F359V or M351T and other sites e.g. 
residue Q459 or F486 [20]. 
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Figure 8 [37] shows clinically relevant point mutations assigned to their position within the ABL1 
TKD. P = p-loop, B = imatinib binding site, C = catalytic domain, A = activation loop. 
 
1.1.5.1 Origin of imatinib resistance and CML stem cells 
 
Since CML is a stem cell disorder, a complete cure of disease requires the 
eradication of progenitor cells as a source of more differentiated CML cells [52]. 
CML stem cells are characterized as CD34+, CD 38- Lin-  leukemic stem cells 
(LSCs) and express high levels of BCR-ABL1 transcripts [20]. Unfortunately, 
imatinib as well as the second generation TKIs nilotinib and dasatinib do not 
efficiently target CML stem cells and these cells remain viable [53-55].  
The CML stem cell population is hypothesized to be the reason for minimal 
residual disease detectable over years of therapy [33]. Moreover, it has been 
shown that discontinuation of TKI treatment, even in patients who achieved a 
complete molecular response (undetectable BCR-ABL1 transcripts by real-time 
and/or nested PCR) results in relapse [56]. This indicates that more 
undifferentiated CML cells possessing self-renewal capacity, are still present 
and can re-establish the disease [24].   
As described for more mature CML cells, there are several factors inducing 
resistance in CML stem cells. This again includes overexpression of BCR-
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ABL1, drug transporter-related mechanisms, loss of tumor suppressor gene 
products and BCR-ABL1 mutations in stem cell subclones [57]. Additionally, it 
has been observed that subpopulations of neoplastic stem cells are in a 
quiescent state of cell cycle, where cell-cycle specific drugs and TKIs are not 
effective [57]. CML stem cells may also be capable of trans-differentiating 
microenvironmental cells which, in turn, might render survival and growth of 
leukemic stem cells possible [57]. 
Concerning the evolution of point mutations, it has been observed that these 
mutations already pre-exist in CML stem cells [58]. This observation provided 
the basis for the hypothesis that the appearance of point mutated clones is 
comparable to antibiotic resistance in bacteria: imatinib selects for these rare 
pre-existing cells and induces outgrowth of drug-resistant cells [59].  
 
1.1.5.2 Overcoming BCR-ABL1 TK point mutation induced resistance  
 
Depending on the type of point mutation and its position within the BCR-ABL1 
sequence, different strategies are available to overcome imatinib resistance. 
Mutations displaying lower levels of resistance might be overcome by dose-
escalation of the drug. This was described to be successful in the presence of 
e.g. M244V, Q252H, M351T, F359V [24,40,60]. 
 
However, there remains the issue of point mutations displaying higher degrees 
of resistance, where increased doses of imatinib fail. In these instances, the 
application of second generation TK inhibitors represents a reasonable option. 
Nilotinib and dasatinib were already tested in a variety of clinical studies, and 
are important candidate drugs. 
Nilotinib (Tasigna®, Novartis Pharmaceuticals) was designed as a derivative of 
imatinib and allows a better topographic fit to ABL1, thereby overcoming 
imatinib resistance due to TK point mutations [61]. In-vitro studies showed that 
the drug selectively inhibits the proliferation of imatinib-resistant BCR-ABL1 
expressing cells and the autophosphorylation of imatinib-resistant BCR-ABL1 
mutants [62]. It is described to be ~ 20-fold more potent against WT and mutant 
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BCR-ABL1 expressing cells than imatinib [63]. Similar to imatinib, nilotinib was 
demonstrated to bind to the ABL1 inactive conformation.  
Considering the clinical applicability of the drug, nilotinib was tested in the 
second-line setting in CP and AP imatinib-resistant CML patients and turned out 
to be an effective and well tolerated treatment modality [64,65]. Moreover, there 
are ongoing studies investigating the use of nilotinib in the frontline setting [66-
68]. Concerning the performance in case of BCR-ABL1 TK point mutations, it 
was observed that patients revealing E255K/V, Y253F/H or F359C/V had a less 
favorable outcome [66] whereas in case of T315I, complete resistance was 
observed [62,63]. 
Dasatinib (Sprycel®, Bristol-Myers Squibb) is a multi-target TKI that inhibits, 
besides BCR-ABL1 TK, the Src family kinases, Kit, PDGFR and ephrin A 
receptor kinase [31]. It was described to be ~ 325 fold and ~ 16 fold more 
potent than imatinib and nilotinib against WT BCR-ABL1, respectively [63]. 
Dasatinib possesses a different chemical scaffold and can bind to both, the 
active and inactive ABL1 conformation, in contrast to imatinib and nilotinib [48]. 
In vitro experiments showed that dasatinib lacks critical interactions with the 
ABL1 p-loop indicating that imatinib-resistant mutations within this region may 
not be relevant [48]. However, T315 is an important dasatinib contact residue, 
implying that mutations occurring at this specific AA position result in dasatinib 
insensitivity [48]; the same holds true for AA position T317. These experimental 
data were confirmed in clinical studies, identifying Q252H, E255K/V, V299L and 
F317L as less sensitive and T315I as completely insensitive to the drug [66].  
The successful implementation of dasatinib as a second-line treatment option 
was demonstrated in a number of clinical studies [66,69]. Two ongoing studies 
investigate the use of dasatinib in the first-line setting [66]. 
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Figure 9 displays the position of TKI inhibitors imatinib, nilotinib and dasatinib within the ABL1 
TK domain. A) Critical residues for ABL1-TK point mutations associated with imatinib- 
insensitivity (e.g. E255, G250, Y253, H396) or resistance (T315) are shown for imatinib [29]. B) 
AA residues in red indicate the positions of point mutations described to be insensitive to 
imatinib but sensitive to nilotinib. Mutations at E255 and Y253 (in green) show a intermediate 
resistance, but those at T315 are completely resistant [70]. C) Critical AA residues for dasatinib 
associated with insensitivity are shown in brown (e.g. F317 and V299); T315I, displayed in red, 
is resistant to dasatinib [70]. 
 
 
 
Despite the success of imatinib, nilotinib and dasatinib for the induction of 
hematologic, cytogenetic and molecular responses in CML patients, point 
mutation T315I remains insensitive to all drugs available. To overcome this 
problem, several alternatives have been pursued as reviewed, for exemple, by 
Quintás-Cardama and Cortes in 2008 [71]:  
This can involve two strategies: a) direct BCR-ABL1 T315I kinase inhibitors 
and/or b) inhibitors of BCR-ABL1 T315I kinase downstream effectors. 
 
A) Imatinib B) Nilotinib C) Dasatinib 
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a) Direct BCR-ABL1 T315I inhibitors: 
 
Aurora-A and Aurora-B are two serine/threonine kinases described to be 
overexpressed or amplified in leukemias. It has been shown that inhibitors of 
both enzymes target WT and mutants of BCR-ABL1. Several inhibitors were 
already tested in in-vitro and in-vivo studies including patients with T315I 
mutation. 
ABL1 switch pocket inhibitors regulate conformational changes involved in 
kinase activity and avoid a steric clash with the T315I-mutated residue. Cross- 
reaction with other kinases is highly reduced since switch pocket structures are 
distinct in all kinases [72]. Clinical trials have not been performed yet.  
Several other preclinical T315I inhibitors are in development.  
 
b) Inhibitors of BCR-ABL T315 kinase downstream effectors 
 
Targeting BCR-ABL1 downstream signalling molecules is an alternative 
treatment option that is not influenced by mutations at the gatekeeper residue 
T315.  
BCR-ABL1 activates the RAS/RAF pathway which is therefore a potential target 
site. It has been shown that the combination of farnesyl transferase inhibitors 
and imatinib had clinical activity against the T315I mutation [71,73].  
The inhibition of RAC GTPases, which are activated in CP CML patients, was 
demonstrated to be successful in a murine model and in in-vitro experiments 
using bone marrow cells from BP CML patients. Thus RAC GTPases seem to 
be an attractive target to prevent BCR-ABL1 signalling [71]. 
Further approaches include the stabilization of protein phoshatase 2A, a BCR-
ABL1 antagonizing tumor suppressor [74] and the activation of apoptotic 
pathways [71]. 
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Independent of the molecular targeting of T315I-resistant BCR-ABL1 molecules, 
epigenetic approaches are on the way rendering the induction of cytogenetic 
and molecular responses even in patients with the highly TKI-resistant T315I 
mutation possible [71].  
 
Allogeneic stem cell transplantation (SCT) represents a possible treatment 
option in case of T315I point mutations and it has been shown that it provides 
long-term disease eradication and prolonged disease-free survival [34,75]. 
However, SCT is not applicable in all patients due to limitations regarding 
suitable donors, advanced age of patients and concerns about treatment-
related morbidity and mortality (graft-versus-host disease, infection and organ 
toxicity) [34]. 
 
An algorithm of the treatment approach in CML patients including different 
drugs and their limitations was proposed by Jabbour et al. [66], and is displayed 
in Figure 10.  
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Figure 10. [66] Treatment strategy in CML patients. CHR = complete hematologic response; 
MinCyR = minimal cytogenetic response; MCyr = major cytogenetic response; CCyR = 
complete cytogenetic response; COPD = chronic obstructive pulmonary disease. Detailed 
explanations for CHR, MinCyR, MCyr, CCyR are described in Table 1. 
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1.2 Methodologies for CML monitoring and detection 
/quantification of point mutations 
 
1.2.1 Methodological tools for CML monitoring 
 
Initial diagnosis of CML is followed by immediate onset of first-line therapy. To 
date, imatinib represents the standard first-line drug applied independently of 
patient-related factors, like age or disease related variables [33]. Imatinib 
induces response rates superior to earlier treatment approaches [32]. The 
response is documented by hematologic analysis including blood count and 
differentials, cytogenetic analysis detecting the percentage of Ph+ positive 
metaphases in the bone marrow, FISH (fluorescence in-situ hybridization) 
revealing the percentage of Ph+ positive interphases and quantitative RT-real-
time PCR permitting the monitoring of BCR-ABL1 transcripts [33].   
An international group of CML experts established an organization, the ELN 
(European LeukemiaNet), that develops concepts and management 
recommendations for CML, defines criteria of response/relapse and provides 
guidelines for the intervals of diagnostic analysis [35]. 
Criteria for hematologic, cytogenetic and molecular response are depicted in 
Table 1. 
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Type of response                                                           Definition                                
 
 
Hematologic 
 
Complete (CHR)    WBC (white blood cell count) < 1x109/L  
      Basophils < 5% 
      No myelocytes, promyelocytes or myelo- 
      blast in the differential 
      Platelet count < 450x 109/L 
      Spleen nonpalpable 
 
 
 
Cytogenetic 
 
Complete (CCgR)    No Ph+ metaphases 
Partial (PCgR)     1-35% Ph+ metaphases 
Minor (mCgR)     35-65% Ph+ metaphases 
Minimal (minCgR)    66-95% Ph+ metaphases  
None (noCgr)     > 95% Ph+ metaphases 
 
 
 
Molecular 
 
Complete (CMolR)    undetectable BCR-ABL1 mRNA transcripts 
      by real-time quantitative and/or nested-PCR 
      in two consecutive blood samples of adequate 
      quality (sensitivity > 104 )  
 
Major (MMolR)     Ratio of BCR-ABL1 to ABL1 (or other house- 
      keeping genes) ≤ 0,1% on the 
      international scale 
 
 
 
                                                                                                                                                                      
 
Table 1. [35]  Definitions of hematologic, cytogenetic and molecular response according 
to the ELN criteria. Adapted from Baccarani et al. 2009. 
 
 
 
 
 
 
 
 
Introduction                                                                                                            Sandra Preuner 
 34 
Moreover, the ELN recommends the intervals for hematologic, cytogenetic and 
molecular analysis after CML diagnosis [35]. 
Hematologic analysis is to be performed initially at diagnosis and then every 15 
days until a complete hematologic response is achieved. Subsequently, the 
analysis is recommended every three months. 
Cytogenetic analysis should be carried out after three and six months, and 
thereafter every six months until a complete cytogenetic response is 
documented. Subsequently, cytogenetics is recommended every 12 months if 
molecular monitoring is not available. 
Molecular monitoring should be performed every three months until a complete 
molecular response is obtained and subsequently at least every six months. If 
suboptimal response or treatment failure is observed, mutational screening for 
BCR-ABL1 TKI point mutations is recommended. Since several point mutations 
insensitive or resistant to second generation TKIs have been described, 
mutational analysis must be performed before any change of therapy [35].   
 
1.2.2 Techniques for the detection/quantification of point mutations 
 
A number of methods have been employed to detect point mutated clones in 
CML. This includes, for example, PCR amplification coupled with direct 
sequencing of the BCR-ABL1 TK domain [76-78], high-performance liquid 
chromatography (D-HPLC) [79-81], the SEQUENOM MassARRAY system [82], 
or allele-specific oligonucleotide (ASO)-PCR amplification [83-85]. These 
techniques display different detection limits for the identification of mutant 
clones ranging from 0.01-30%. Detection of a mutation within the ABL1 TK 
domain does not necessarily imply impending onset of clinically resistant 
disease, particularly if the size of a mutant clone is small [85]. Mutant clones 
have been reported to disappear spontaneously which may, at least in part, be 
attributable to the occurrence of mutations in cells with restricted proliferative 
capacity [77,83]. 
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Qualitative methods for mutational analysis may therefore have limited potential 
to reliably assess the risk of clinically resistant disease, especially if mutant 
clones present at very low levels are detected [83].  
It is currently a matter of discussion whether the detection of small mutant BCR-
ABL1 clones, e.g. below the level of 1%, is clinically useful. The clinical benefit 
of sensitive techniques for mutational analysis could be increased if the size of 
mutant clones could be monitored, in order to facilitate timely detection of 
clonally expanding mutant cells during treatment [83].  
Current approaches to assessing the size of mutant clones include e.g. 
pyrosequencing [77], SEQUENOM MassARRAY analysis [82], or the 
polymerase colony assay [86]. These techniques, however, have limitations 
with regard to broad application in clinical diagnosis, such as the requirement of 
very expensive equipment [82], rather complex and laborious design [86], or the 
apparent inability to quantify mutant clones in the range below 20% [77]. 
 
1.2.3 Technical basis for the development of LD-PCR and Hybprobe/PNA 
assay 
 
MLPA (multiplex ligation-dependent probe amplification) technology was first 
described by Schouten et al. in 2002 [87]. This technique facilitates relative 
quantification of up to 40 different DNA sequences within one reaction. For each 
target region two oligonucleotides are generated, one synthetic and one M13- 
derived. The M13-derived oligonucleotides possess stuffer-sequences of 
different lengths rendering the discrimination of different targets within a 
multiplex reaction possible. Oliogonucleotides adjacently hybridize to the target 
site followed by a ligation step mediated by a specific ligase (Ligase 65), which 
is very sensitive to probe-targeted mismatches next to the ligation site [87]. The 
oligonucleotides have identical end-sequences and serve as a target site for 
universal forward and reverse primers. Thereafter, amplification by a PCR 
reaction is performed and amplicons are analyzed by capillary electrophoresis.  
To date, hundreds of different MLPA-based detection kits are commercially 
available and facilitate the assessment of scientific or clinical questions 
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including congenital and hereditary disorders, tumor and methylation profiling, 
as well as quantification of mRNA (www.mlpa.com).  
In their publication, Schouten et al. described the possibility to use the MLPA 
technology for SNP (single nucleotide polymorphism) and mutation detection. 
This provided the basis for the idea to adapt the MPLA technology to assays 
which facilitate not only the sensitive detection but also the quantification of 
point mutated subclones.  
PNA oligonucleotides used for the PNA/Hybprobe approach consist of 
nucleotide bases provided with a pseudopeptide backbone instead of a sugar-
phosphate backbone [88]. These oligonucleotides were described to form stable 
structures with complementary DNA and RNA [89] with high affinity and 
specificity, which is mainly attributable to the uncharged and flexible polyamide 
backbone [90]. PNA oligos are used for a plethora of technologies, including 
e.g. FISH and PCR  [90]. 
PNA clamping was first described by Ørum in 1993 [91]: a PNA oligo was 
designed to bind to its complementary target sequence and thus prevented its 
amplification within a PCR reaction. This was enabled by either competitive 
binding to the respective primer sequence, or by physical blocking of the DNA 
polymerase resulting in the inhibition of the PCR elongation step [92]. Moreover, 
a combination of PNAs with Hybprobes® (Roche) was described for the specific 
and sensitive detection of point mutated sequences within the RAS oncogene 
[93,94]. 
The LightCycler®Hybprobe format relies on two sequence-specific probes 
(anchor and sensor probe) which are labelled by different fluorescence dyes. 
The sensor probe is labelled with a 3´ fluorescein, the anchor with 5´ 
LightCycler®Red. During the PCR annealing phase, they hybridize adjacently to 
each other and a FRET (fluorescence resonance energy transfer) reaction 
takes place. Thereby fluorescein, excited by light from a LED lamp (part of the 
LightCycler PCR machine), transfers energy to the 5´LightCycler®Red at the 
anchor probe. The anchor probe thereby emits red fluorescent light, which is 
subsequently measured. After the PCR amplification reaction is finished, a 
melting curve program is activated. Starting at about 40°C, the PCR machine 
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gradually increases the temperature and the double stranded PCR amplicons 
start to disintegrate. The temperature at which half of the amplicons are present 
in double stranded form and half are single-stranded is defined as the melting 
temperature, which is characteristic for each sequence (www.roche-applied-
science.com). 
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Specific aims 
 
- Development of novel methodological approaches to sensitive detection 
and/or quantitative monitoring of point-mutated clones in CML patients 
with known TKI mutations based on the MLPA-related ligase-dependent 
(LD-)-PCR or the implementation of PNA oligonucleotides 
- Proof of feasibility to adapt the LD-PCR technique to the analysis of any 
point mutation by developing an approach to the detection/quantification 
of V617F within the JAK2 gene in patients with myeloproliferative 
disorders 
 
 
Working hypothesis 
 
Point-mutanted subclones may not imply resistance to TKI therapy simply by 
their presence in peripheral blood or bone marrow samples. Various models 
suggest that subclones with known TKI resistance might proliferate prior to the 
onset of clinically detectable resistance. In contrast, point-mutated subclones 
incapable of inducing TKI-resistance and progression of disease might 
decrease in size and ultimately disappear or persist on a low level [95]. 
The technique to be developed (LD-PCR) should provide the basis for sensitive 
detection and quantitative monitoring of point-mutated subclones to document 
their proliferation kinetics. The documentation of an expanding mutant subclone 
is indicative of its resistance to current TKI therapy, and could therefore serve 
as a basis for timely treatment modification. 
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2 Materials and Methods 
 
2.1 PCR amplification of BCR-ABL1 sequences 
 
Semi-nested PCR reactions were performed as described previously [76]. The 
PCR reaction for the first round of amplification included 0,3 µM  forward primer 
1 (5’-TGACCAACTCGTGTGTGAAACTC-3’), 0,3 µM reverse primer (5’-
TCCACTTCGTCTGAGATACTGGATT-3’), 0,5 mM dNTPs, 0,75 mM MgCl2, 2U 
Expand Long Template Polymerase, 10 x buffer 3 (Expand Long template PCR 
system, Hoffmann-La Roche Ltd, Basel, Switzerland), and 150 ng cDNA 
template in a total volume of 25 µl. In the presence of the e1a2 BCR-ABL 
fusion, the same concentration of a different forward primer (5’-
ACCGCATGTTCCGGGACAAAAG-3’) was used. The first PCR round was 
performed according to the following protocol: preheating to 94°C, followed by 2 
min at 94°C, 10 cycles with the profile of 94°C for  20 sec, 60°C for 30 sec, 68°C 
for 2 min, 25 cycles with the profile of 94°C for 2 0 sec, 60°C for 30 sec, 68°C for 
2 min + 20sec/cycle, a final extension step at 68°C  for 7 min with subsequent 
cooling to 10°C. For the second round of amplificat ion, 1 µl of the first-round 
PCR product was added to a reaction mix identical to the above indicated, a 
nested forward primer (5’-CGCAACAAGCCCACTGTCT-3’) at 0,3 µM being the 
only difference. The second round of PCR was performed according to the 
following protocol: preheating to 94°C, 2 min at 94 °C, 10 cycles with 94°C for 20 
sec, 60°C for 30 sec, 68°C for 1 min, 25 cycles wit h 94°C for 20 sec, 60°C for 
30 sec, 68°C for 1 min + 20sec/cycle, a final exten sion step of 68°C for 7 min 
followed by cooling to 10°C.  
 
 
Materials and Methods                                                                                           Sandra Preuner 
 42 
2.2 LD-PCR approaches 
 
For LD-PCR analysis, reaction mixes were prepared on ice. All reagents were 
components of the Salsa® MPLA® reagents kit (MRC Holland, Amsterdam, The 
Netherlands), containing basic reagents except ligation and hybridization oligos. 
For the first step, 0,5 µl probe mix [containing 0,8 µl from 1µM concentrations of 
each Lig-WT probe, Lig-Mut probe and Hyb probe (Sigma, Steinheim, 
Germany) in 200 µl H2O], 1,5 µl of MLPA buffer and 50 ng of the BCR-ABL1 
PCR product (determined by photometric measurement) were mixed and 
immediately subjected to a hot-start at the ABI 9600 thermocycler (Applied 
Biosystems (AB), Foster City, USA) for 5 min at 98°C in order to prevent the 
formation of secondary structures. For hybridization of Lig-WT, Lig-Mut and 
Hyb-oligonucleotide, the reaction mix was cooled down to the appropriate 
hybridization temperature listed in Table 3, and incubated for 1 min. For ligation 
procedure performed at 54°C for 15 min., 32 µl of a  ligation-mix containing 3 µl 
Ligase-65 buffer A, 3 µl Ligase-65 buffer B, 1 µl Ligase 65 and 25 µl water were 
added and mixed properly. This step was followed by enzyme inactivation for 5 
min at 98°C and cooling of the samples to 4°C. A mi xture of 4 µl 10x SALSA 
PCR buffer and 26µl sterile water was added to 10 µl of the ligation reaction 
heating to 60°C to prevent non-specific primer anne aling, and supplemented 
with 10 µl of the PCR-mix containing 2 µl FAM-labelled SALSA PCR primers, 2 
µl SALSA enzyme dilution buffer, 0,5 µl SALSA polymerase and 5,5 µl sterile 
water. The LD-PCR program was started according to the following protocol: 
95°C for 30 sec, 60°C for 60 sec, 72°C for 60 sec f or 35 cycles, 72°C for 20 
min, and cooling to 4°C.  
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2.3 Capillary electrophoresis 
 
Analysis of LD-PCR products was performed on the ABI PRISM 3100-Avant 
Genetic Analyzer (Applied Biosystems (AB) Foster City, USA). The set up of the 
instrument was done according to the manufacturer´s instructions. Due to the 
FAM label of the SALSA fw primer, DS-01 Matrix Standard Set for the 3100 and 
3100-Avant Systems (AB) was used to establish a matrix file (dyset D). A 36 cm 
capillary column containing the high performance polymer POP-4TM (AB) was 
used for PCR product separation. The LD-PCR product was diluted 1:50 using 
Aqua bidestillata (Mayerhofer Pharmazeutics, Linz, Austria). To identify the 
PCR products according to their lengths in bp, a reaction mix containing 0,3 µl 
GeneScan™-500 ROX™ Size Standard (AB) and 9 µl Hi-Di™ Formamide (AB) 
was prepared and 1 µl of the diluted PCR product was added. The reaction was 
denatured at 94°C for 3 min, and cooled to 4°C. Amp licon separation on the ABI 
PRISM 3100-Avant was performed using an injection time of 10 s, injection 
voltage of 1 kV, electrophoresis voltage of 10 kV, and an oven temperature of 
60°C. In case of off-scale results, the injection w as repeated using lower 
injection time and voltage.  
 
2.3.1 Analyses of capillary electrophoresis results 
 
The ABI PRISM GeneScan Analysis software 3.7 (AB) was used to analyze 
the results obtained by capillary electrophoresis. Due to the stuffer sequence 
inserted within the MUT Lig-oligo, the PCR product amplified from the MUT 
sequence was six base pairs longer than the WT product. Peak heights of WT 
and MUT amplicons were used for the calculation of relative amounts. This ratio 
was calculated using the following formula: % Mut = (peak height of Mut 
product/ ∑ peak heights of Mut + WT products) x 100.  
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2.4 Patient material 
 
2.4.1 RNA extraction and cDNA synthesis  
 
Peripheral blood anticoagulated with EDTA was collected from CML patients 
revealing suboptimal response to imatinib and control patients with adequate 
response to treatment. Leukocyte counts were determined using the Sysmex 
KX-21N system (Sysmex Austria GmbH, Vienna, Austria). Erythrocytes were 
lysed by red cell lysis buffer ([10 mM Tris (pH 7,6), 5 mM MgCl2, 10 mM NaCl] 
(Sigma, Steinheim, Germany)), and the leukocytes were pelleted by 
centrifugation for 10 min at 1 300 rpm. Total RNA was extracted from 2x107 
leukocytes using the QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer´s instructions.  
cDNA synthesis was performed using 10 µl of reverse transcriptase mix 
including  MMLV-RT 5x buffer, 0,2 mM dNTPs, 0,25 µg random primers, 20 U 
RNAsin, 100 U MMLV Reverse Transcriptase (all Promega, Mannheim, 
Germany) and 10 µl of total RNA. The reaction was incubated for 1 h at 37°C. 
Assessment of cDNA concentration was performed by Nanodrop measurement.  
 
2.4.1.1 RNA extraction from methanol/acetic acid-fixed cells 
 
200-500 µl of the cell suspension from methanol/acetic acid-fixed cells were 
pelleted at 13 000 rpm for 5 min. The supernatant was removed completely and 
1 ml 96% ethanol was added without agitating. Again, the cells were pelleted as 
described and the supernatant was removed. Cells were resuspended in 350 µl 
RLT-buffer provided with the QIAamp RNA Blood Mini Kit (Qiagen) and further 
steps were performed as described by the manufacturer. 
 
Materials and Methods                                                                                           Sandra Preuner 
 45 
2.4.2 Real-time PCR analysis of BCR-ABL1 and control gene  
 
To determine the quantity of BCR-ABL1 transcripts in relation to the control 
gene ABL1, quantitative real-time PCR analysis was performed as already 
described [96]:  for major BCR-ABL1 (Mbcr) 300 nM Mbcr fw primer (5´ 
TCCGCTGACCATCAAYAAGGA 3´), 200 nM Mbcr probe (5´ Fam-
CCCTTCAGCGGCCAGTAGCATCTGA-Tamra 3´), 300 nM Mbcr rev primer (5´ 
CACTCAGACCCTGAGGCTCAA 3´), 2 x LC-480 probes mastermix and 0,5 U 
Uracil-DNA Glycosylase (Roche Diagnostics, Penzberg, Germany) were used. 
For minor BCR-ABL1 (mbcr) and ABL1 (abl) the reaction components remained 
the same with the exception of primers and probes: i) mbcr: 300 nM mbcr fw 
primer (5´ CTGGCCCAACGATGGCGA 3´), 200 nM mbcr probe (5´ Fam-
CCCTTCAGCGGCCAGTAGCATCTGA-Tamra 3´), 300 nM mcbr rev primer (5´  
CACTCAGACCCTGAGGCTCAA 3´) and ii) abl: 300 nM abl fw primer (5´ 
TGGAGATAACACTCTAAGCATAACTAAAGGT 3´), 200 nM abl probe (5´ Fam-
CCATTTTTGGTTTGGGCTTCACACCATT-Tamra 5´), 300 nM abl rev primer 
(5´ GATGTAGTTGCTTGGGACCCA 3´). The RT-PCR reactions were amplified 
according to the LightCycler standard program: pre-amplification for 10 sec. at 
95°C; 50 amplification cyles for 10 sec. at 95°C, 3 0 sec. at 60°C, 10 sec. 72°C; 
followed by cooling to 4°C.   
For calculation, results obtained for the rearranged transcripts were correlated 
to 1x 105 ABL1 molecules [(1x 105 * BCR/ABL1 molecules)/ABL molecules], 
additionally the BCR-ABL1/ABL1 (%) ratio was indicated: (BCR-
ABL1/ABL1)*100. 
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2.4.3 Detection of point mutated sub-clones via bidirectional sequencing 
 
The presence of ABL1 TK point mutations was verified by bidirectional 
sequencing of the BCR-ABL1 TK domain prior to LD-PCR analysis. Initially, the 
first round of semi-nested PCR was prepared as described above. In case of 
low starting amount of BCR-ABL1, a second round of PCR amplification had to 
be performed. The PCR product was analyzed on a 1,5% agarose gel and the 
respective band [first round products b2a2 (Mbcr): 1504 bp; b3a2 (Mbcr): 1579 
bp; e1a2 (mbcr): 1641 bp; second round product: 863 bp] was eluted from the 
gel using the QIAquick PCR Purification Kit (Qiagen) according to the 
manufacturer’s instructions. PCR products were subjected to bidirectional 
sequencing (VBC Genomics, Vienna, Austria) using the primers NTBP+ (5´ 
AAGCGCAACAAGCCCACTGTCTAT 3´) and NTBP- (5´ 
CTTCGTCTGAGATACTGGATTCCTG 3´). The presence of point mutations 
was determined by comparing the patient sequence, with the reference 
sequence (>gi|62362413:4-3396 Homo sapiens v-abl Abelson murine leukemia 
viral oncogene homolog 1 (ABL1), transcript variant a, mRNA) using the BLAST 
program (http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi).
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3 Results 
 
3.1 LD-PCR 
 
3.1.1 Design of LD-PCR oligonucleotides 
 
3.1.1.1 Methodological principle of LD-PCR approaches  
 
The principle of LD-PCR relies on a ligation-dependent competitive PCR 
approach. This newly developed technique is a modification of the MLPA 
technique described by Schouten et al in 2002 [87]. Competitive hybridization of 
WT/MUT specific ligation (Lig) oligonucleotides and a common hybridization 
(Hyb) oligonucleotide is followed by a ligation step. Thereby adjacent Lig- and 
Hyb-oligonucleotides are conjugated to form a continuous template for the 
subsequent PCR amplification applying universal primers. The amplification 
products are separated and detected by capillary electrophoresis. 
Probe sets required for each LD-PCR approach consist of two Lig- and one 
Hyb-oligonucleotide. Lig-oligonucleotides bind specifically to the 5´ region of the 
particular point mutation. While one oligonucleotide hybridizes to the WT 
sequence (Lig-WT), the other one is specific for the mutated sequence (Lig-
MUT). Lig-WT and Lig-MUT oligonucleotides differ in a single nucleotide located 
at their 3´terminal position. An additional “stuffer” sequence is attached at the 5´ 
site of the Lig-MUT oligonucleotide, and consists of six nucleotides not 
complementary to the DNA target sequence. Hence, the Mut-PCR product is six 
bp longer than the WT product and this renders the discrimination of Mut- and 
WT-specific LD-PCR products by capillary electrophoresis possible. A universal 
template sequence facilitating the binding of a universal forward primer is 
attached at the 3´ terminal end of the Lig-oligonucleotide. The Hyb- 
oligonucleotide is located adjacently to the 3´ end of the Lig-oligonucleotides 
and as a prerequisite for ligation, the 5´ end is phosphorylated.  
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Accordingly, the universal template sequence, facilitating the annealing of a 
universal reverse primer is attached at the 3´ terminal end of the Hyb-
oligonucleotide. The arrangement of Lig-WT, Lig-MUT and Hyb-oligonucleotide 
and the principle of the LD-PCR approach are displayed in detail in Figure 11.  
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Figure 11. LD-PCR assay for the sensitive detection and quantification of wild-type (WT) 
and point-mutated (MUT) sequences. The principle of LD-PCR is a modification of the MLPA 
technology [87]. The LD-PCR reaction contains three different probes: 1) The wild-type ligation 
probe (Lig-WT) contains a section complementary to the WT target sequence [b] and a tag 
sequence for the forward primer [a]. 2) The ligation probe for the mutant sequence (Lig-MUT) 
[b*] differs from the Lig-WT probe by a nucleotide at the 3´ terminal position complementary to a 
specific point mutation. This probe carries the same tag sequence [a] for the forward primer, but 
contains an additional stuffer sequence of 6 non-homologous nucleotides [c]. 3) The common 
hybridization (Hyb) probe contains a section complementary to its target sequence directly 
adjacent to that of the ligation probes [d] and a tag sequence for the reverse primer [e]. Upon 
specific hybridization to the target sequence, the probes are fused under conditions described in 
Materials and Methods, permitting the ligation only in the presence of perfect match to the target 
sequence. In a subsequent step, the ligated probes are amplified competitively in a PCR 
reaction with a single set of primers binding to the tag sequences a+e. Due to the difference in 
length between the WT- and MUT-derived products, the amplicons can be readily separated 
and quantified by fluorescent capillary electrophoresis (see Fig.2). 
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3.1.2 Rules for oligonucleotide design 
 
For the design of Lig- and Hyb- oligonucleotides, a number of criteria have to be 
considered. Probes must never overlap, the length of each oligonucleotide has 
to be more than 21 nucleotides, the melting temperature ≥ 70°C, the G/C 
content should be around 50% and the two hybridizing sequences have to be 
immediately adjacent. A specific program, available at www.mlpa.com, permits 
the verification of the design according to the criteria described. The forward 
primer (5’-GGGTTCCCTAAGGGTTGGA-3’) is designed to be complementary 
to the tag sequence at the 5’ end of the Lig probe, and the reverse primer (5’-
GTGCCAGCAAGATCCAATCTAGA-3’) to the tag sequence at the 3’ end of the 
Hyb probe, as indicated.  
In some instances, the above rules for probe design had to be modified due to 
the base composition around the site of mutation in order to provide optimal 
performance of individual probe systems. This was mainly attributable to the 
phenomenon of hybridization of unrelated bases, which is well documented 
(Table 2).  
 
Base 
Base on 
complementary      
strand 
Ligation 
between 
the 
bases 
C no 
T no G 
A 25% 
A no 
G no T 
C 25% 
A no 
G no C 
T possible 
T no 
G no A 
C no 
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Table 2. Ligation of unrelated bases. Displayed are the options for ligation reactions between 
the normal nucleotide and the nucleotide of the polymorphic sequence on the complementary 
strand as described by MRC Holland (www.mlpa.com). 
 
Primarily, the oligonucleotides were designed in a sense-orientated fashion, and 
the assays were tested for functionality, using synthetic templates containing 
the target region of interest (data not shown.) In case of high cross-reactivity 
with the WT sequence, the systems were re-designed in an antisense-
complementary fashion. This was necessary for some LD-PCR systems for the 
following mutations: Q252H-T, Q252H-C, F359V, H396R and H396 P.  
  
To exclude the formation of secondary structures close to the hybridization 
temperature, each oligonucleotide/universal template construct was controlled 
using the program http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/dna-
form1.cgi. Default analysis parameters were used except for ionic 
concentration, ([Na+] was set at 0,35M) and the folding temperature, which was 
set at the appropriate hybridization temperature of the Lig- and Hyb- 
oligonucleotides.  
 
In general, the WT and MUT Lig-oligonucleotides, as well as hybridization 
oligonucleotides were designed to hybridize at a temperature of 70°C. However, 
due to the high G/C content of surrounding DNA regions, the hybridization 
temperature had to be increased to 75°C in some ins tances. This was mainly 
necessary for several point mutations located within the P-loop of the ABL1 TK 
domain (E255K, Y253F, Y253H, Q252H-C and Q252H-T) or within the 
activation loop (H396P and H396R).  
 
The final LD-PCR oligonucleotide sequences, the calculated and employed 
hybridization temperature, G/C content and lengths are depicted in Table 3.  
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LD-System Primer     Stuffer    Oligo Hybridizationtemperature C° Lig/Hyb oligo properties 
E255K     lengths (bp) G/C content (%) TM (°C) 
Lig Oligo WT gggttccctaagggttggacgggggccagtacgggg 75 17 82 76 
Lig Oligo Mut gggttccctaagggttggattcaatcgggggccagtacggga    17 76 74 
Hyb Oligo 5´Phos aggtgtacgagggcgtgtggaagtctagattggatcttgctggcac   23 61 74 
Y253F           
Lig Oligo WT gggttccctaagggttggagctgggcgggggccagta 75 18 78 76,6 
Lig Oligo Mut gggttcccgaagggttggatagtccgctgggcgggggccagtt   18 78 77,5 
Hyb Oligo 5'Phos cggggaggtgtacgagggcgtctagattggatcttgctggcac   20 75 77,5 
Y253H           
Lig Oligo WT gggttccctaagggttggactgggcgggggccagt 75 16 81 74,4 
Lig Oligo Mut gggttccctaagggttggatgtggtctgggcgggggccagc   16 88 77,4 
Hybr Oligo 5'Phos acggggaggtgtacgagggcgtctagattggatcttgctggcac   21 71 75,9 
F317L-A           
Lig Oligo WT gggttccctaagggttggagcccccgttctatatcatcactgagttc 70 28 50 72,8 
Lig Oligo Mut gggttccctaagggttggacttatcgcccccgttctatatcatcactgagtta   28 46 71 
Hyb Oligo 5'Phos atgacctacgggaacctcctggatctagattggatcttgctggcac   23 57 71,2 
F317L-G           
Lig Oligo WT gggttccctaagggttggacccccgttctatatcatcactgagttc 70 27 48 70,6 
Lig Oligo Mut gggttccctaagggttggacttatccccccgttctatatcatcactgagttg   27 48 71,1 
Hyb Oligo 5'Phos atgacctacgggaacctcctggatctagattggatcttgctggcac   23 57 71,2 
F317-C           
Lig Oligo WT gggttccctaagggttggacccccgttctatatcatcactgagtt  70 26 46 69,1 
Lig Oligo Mut gggttccctaagggttggattatctcccccgttctatatcatcactgagtg   26 50 70,7 
Hyb Oligo 5'Phos catgacctacgggaacctcctgtctagattggatcttgctggcac   22 59 71,1 
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F317-I           
Lig Oligo WT gggttccctaagggttggagcccccgttctatatcatcactgagt  70 26 50 71 
Lig Oligo Mut gggttccctaagggttggattattggcccccgttctatatcatcactgaga   26 50 70,7 
Hyb Oligo 5'Phos tcatgacctacgggaacctcctgtctagattggatcttgctggcac   23 57 70,8 
F317-V           
Lig Oligo WT gggttccctaagggttggagcccccgttctatatcatcactgagt    26 50 71 
Lig Oligo Mut gggttccctaagggttggattattggcccccgttctatatcatcactgagg 70 26 54 73,1 
Hyb Oligo 5'Phos tcatgacctacgggaacctcctgtctagattggatcttgctggcac   23 57 70,8 
V299L-T           
Lig Oligo WT gggttccctaagggttggacatgaaagagatcaaacaccctaacctgg   29 45 72,2 
Lig Oligo Mut gggttccctaagggttggagttgtgcatgaaagagatcaaacaccctaacctgt 70 29 41 71,1 
Hyb Oligo 5'Phos tgcagctccttgggtctgtctagattggatcttgctggcac   19 63 69,1 
V299L-C           
Lig Oligo WT gggttccctaagggttggacatgaaagagatcaaacaccctaacctgg 70 29 45 72,2 
Lig Oligo Mut gggttccctaagggttggagttgtgcatgaaagagatcaaacaccctaacctgc   29 45 72,2 
Hyb Oligo 5'Phos tgcagctccttgggtctgtctagattggatcttgctggcac   19 63 69,1 
M244V           
Lig Oligo WT gggttccctaagggttggagaacgcacggacatcacca 70 19 58 69,1 
Lig Oligo Mut gggttccctaagggttggatgacctgaacgcacggacatcaccg   19 63 71 
Hyb Oligo 5'Phos tgaagcacaagctgggcggtctagattggatcttgctggcac   19 63 71 
L248V           
Lig Oligo WT gggttccctaagggttggaggacatcaccatgaagcacaagc 70 23 52 70,7 
Lig Oligo Mut gggttccctaagggttggataatctggacatcaccatgaagcacaagg   23 52 70,4 
Hyb Oligo 5'Phos tgggcgggggccagttctagattggatcttgctggcac   15 80 71,2 
G250E           
Lig Oligo WT gggttccctaagggttggatgaagcacaagctgggcgg 70 19 63 70,9 
Lig Oligo Mut gggttccctaagggttggagtgttgtgaagcacaagctgggcga   19 58 68,9 
Hyb Oligo 5'Phos gggccagtacggggaggtctagattggatcttgctggcac   17 76 71,4 
Q252H-T*           
Lig Oligo WT gggttccctaagggttggagccctcgtacacctccccgtac 75 22 68 74,8 
Lig Oligo Mut gggttccctaagggttggatacagagccctcgtacacctccccgtaa   22 64 74 
Hyb Oligo 5'Phos tggcccccgcccagctttctagattggatcttgctggcac   17 76 74,8 
Q252H-C*           
Lig Oligo WT gggttccctaagggttggaagctgggcgggggccag 75 22 68 74,8 
Lig Oligo Mut gggttccctaagggttggatatctcagctgggcgggggccac   22 68 74,7 
Hyb Oligo 5'Phos tacggggaggtgtacgagggcgtctagattggatcttgctggcac   17 76 74,8 
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T315A           
Lig Oligo WT gggttccctaagggttggaggagcccccgttctatatcatca 70 23 52 69,7 
Lig Oligo Mut gggttccctaagggttggatcttatggagcccccgttctatatcatcg   23 57 71,4 
Hyb Oligo 5'Phos ctgagttcatgacctacgggaacctctctagattggatcttgctggcac   25 52 70,3 
T315I           
Lig Oligo WT gggttccctaagggttggaggagcccccgttctatatcatcac 70 24 54 70,9 
Lig Oligo Mut gggttccctaagggttggatcatttggagcccccgttctatatcatcat   24 50 69,5 
Hyb Oligo 5'Phos tgagttcatgacctacgggaacctctctagattggatcttgctggcac   25 52 70,7 
M351T           
Lig Oligo WT gggttccctaagggttggaccactcagatctcgtcagccat 70 22 55 69,3 
Lig Oligo Mut gggttccctaagggttggagatgttccactcagatctcgtcagccac   22 59 70,8 
Hyb Oligo 5'Phos ggagtacctggagaagaaaaacttcatcctctagattggatcttgctggcac   29 45 71,1 
F359V*           
Lig Oligo WT gggttccctaagggttggaggcagcaagatctctgtggatgaa   24 50 70,9 
Lig Oligo Mut gggttccctaagggttggaacgcatggcagcaagatctctgtggatgac 70 24 54 71,6 
Hyb Oligo 5'Phos gtttttcttctccaggtactccatggctctagattggatcttgctggcac   27 48 71,7 
H396P*           
Lig Oligo WT gggttccctaagggttggattgatggggaacttggctccagcat   25 52 74,05 
Lig Oligo Mut gggttccctaagggttggatgaaggttgatggggaacttggctccagcag 75 25 56 75,3 
Hyb Oligo 5'Phos gggctgtgtaagtgtcccctgtctctagattggatcttgctggcac   23 65 75,15 
H396R*           
Lig Oligo WT gggttccctaagggttggattgatggggaacttggctccagcat   25 50 74,05 
Lig Oligo Mut gggttccctaagggttggatgaaggttgatggggaacttggctccagcac 75 25 56 75,37 
Hyb Oligo 5'Phos gggctgtgtaagtgtcccctgtctctagattggatcttgctggcac   23 65 75,15 
     
      
* LD-System reverse complementary         
 
Table 3. LD-PCR detection systems for 21 mutations in the BCR-ABL TK domain. 
*LD-PCR system designed in a reverse complementary fashion. The table includes information on the constitution of each LD-PCR system 
including WT-and Mut-ligation oligonucleotides and Hyb oligonucleotide, the hybridization temperature, lengths (in bp), G/C content (%) and 
calculated melting temperature (TM).   
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3.1.3 Establishment of positive controls/calibrator samples 
 
3.1.3.1 Cloning of the WT BCR-ABL1 TK domain 
 
In vitro mutagenesis was performed to establish positive controls for LD-PCR 
assays. The WT ABL1 TK domain (~ 1kB) was amplified as a template from the 
K562 cell line using 400 mM B2A fw (5’-TTCAGAAGCTTCTCCCTGACAT-3’) 
primer targeting the BCR exon 13, 400 nM JAMR rev (5’-
GTACTCACAGCCCCACGGA-3’) targeting ABL1 exon 10, 10 x ABI buffer, 2,5 
U AmpliTaq® DNA Polymerase, 0,5 mM dNTPs and 5 mM MgCl2 in a total 
volume of 25 µl. The following amplification conditions were used [77]: 10 min. 
at 95°C for initial denaturation; 30 sec. at 95°C, 45 sec. at 50°C, 1 min 20 sec. 
at 72°C for 35 cycles, 10 min. at 72°C, cooling to 4°C. The PCR product was 
analyzed on a 1,5% agarose gel and subsequently eluted from the gel using the 
QIAquick PCR Purification Kit (Qiagen) according to the manufacturer’s 
instructions.  
The purified PCR product was cloned into a pGEMt vector (Promega, 
Mannheim, Germany). To introduce the PCR product into the vector, a ligation 
reaction was performed containing 2 x buffer, 1 µl pGEMt, 1 µl Liagase (all 
Promega) and 3 µl purified PCR product. The ligation reaction was performed 
for 1 h at room temperature. 
For transformation purposes, E. coli chemically competent cells (One Shot® 
Top 10, Invitrogen, Lofer, Austria) were used and thawed on ice for ~ 10 min; 
ligation products were kept on ice. 50 µl One Shot® Top 10 cells were applied 
to the ligation product and incubated on ice for 30 min. The reaction was heated 
to 42°C for 45 sec, cooled on ice for 2 min, adjust ed with 500 µl SOC medium 
and incubated for 30 min at 37°C. Transformed cells  were plated on two LB 
amp plates (100 µg/ml) containing 80 µg/ml X-GAL and 0,5 M IPTG and 
incubated overnight at 37°C. Single white colonies were selected and applied to 
4 ml of liquid LB amp medium and grown overnight at 37°C. The QIAprep Spin 
Miniprep Kit (Qiagen) was used to obtain the ABL1 TK domain-containing 
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plasmid by applying the cell pellet from 2 x 1,5 ml bacterial suspension, 
according to the manufacturer´s instructions. The plasmid concentration was 
determined by photometric measurement using the Nandrop instrument ND-
1000.    
The presence of the ABL1 TK domain was confirmed by direct sequencing in 
both directions (as explained in 2.4.3.) using the primers B2A fw and JAMR rev 
(see above). 
 
3.1.3.2 Mutagenesis assays 
 
To generate 21 different ABL1 TK point-mutated plasmids, mutagenesis assays 
were performed using the QuikChange II Site-Directed Mutagenesis Kit 
(Stratagene, CA, USA). Fw and rev primers required were designed using a 
program provided on the Stratagene website applying the ABL1 TK reference 
sequence (accession number: >gi|62362413:4-3396 [Homo sapiens v-abl 
Abelson murine leukemia viral oncogene homolog 1 (ABL1), transcript variant a, 
mRNA]). 
Primer sequences designed for each ABL1 TK point mutation are listed in Table 
4. Primers were required to be PAGE-purified. The amount of primers 
necessary for mutagenesis PCR reaction was 125 ng each and had to be 
calculated according to the following formula: x pmol primer = [125/(330 x 
number of nucleotides)] x 1000. In addition to fw and rev primers the PCR 
reaction contained: 5 µl of 10 x reaction buffer, 1 µl of dNTP mix, 1 µl of 
PfuUltra HF DNA polymerase (2,5 U) (all Stratagene) and 1 µl of the 1: 100 
diluted WT ABL1 TK plasmid. Amplification was performed according to the 
Stratagene protocol: 30 sec. 95°C; followed by 12 c ycles of 30 sec. 95°C, 1 min. 
55°C, 5 min. 68°C; and cooling to 10°C. To digest t he amplification products 
with Dpn1, the total amount of PCR product was incubated with 10 U DpnI for 1 
h at 37°C, 10 min at 65°C and subsequently cooled o n ice. For transformation 
purposes, XL1-Blue supercompetent cells (Stratagene) were thawed on ice for 
10 min. Each 50 µl were mixed with 1 µl of digestion-product, incubated on ice 
for 30 min, 45 sec at 42°C, cooled on ice for 2 min , mixed with 500 µl SOC 
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medium and incubated for 30 min at 37°C. Transforme d cells were 
subsequently plated on LB amp plates and incubated overnight at 37°C. Single 
colonies were taken and incubated in 4 ml LB liquid medium overnight at 37°C.  
Plasmid preparation was performed using the QIAprepSpin Miniprep Kit 
(Qiagen), using the pellet of 2 x 1,5 ml bacterial suspension, according to the 
manufacturer´s instructions. The plasmid concentration was determined by 
photometric measurement using the Nandrop instrument ND-1000.    
To control for the success of nucleotide exchange, direct sequencing in both 
directions was performed (VBC Genomics, Vienna, Austria) using the NTBP+ fw 
primer (5´ AAGCGCAACAAGCCCACTGTCTAT 3´) [77]. Depending on the 
position of the point mutation within the ABL1 TK sequence the following 
reverse primers were used: AA position 237 – 351 rev primer abl mid rev (5´ 
GCAGTTTCGGGCAGCAAGATC 3´); AA position 351 – end, rev primer NTBP- 
rev (5´ CTTCGTCTGAGATACTGGATTCCTG 3´) [77]. The sequence obtained 
after sequencing reaction was compared to the WT ABL1 TK sequence using 
the “bl2seq” within the BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
In case of successful mutation reaction, the chromatogram was analyzed using 
the freely available “Chromas lite” program for additional verification. 
For storage purposes the remaining bacterial suspension (+ 80% glycerine) was 
frozen on -80°C.  
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Mutation Base exchange Fw primer (5´-3´) Rev primer (5´-3´) 
E255K GAG → AAG gggccagtacgggaaggtgtacgaggg ccctcgtacaccttcccgtactggccc 
Y253F TAC → TTC tgggcgggggccagttcggggagg cctccccgaactggcccccgccca 
Y253H TAC → CAC gcgggggccagcacggggaggtg cacctccccgtgctggcccccgc 
F317L-A TTC → TTA cccgttctatatcatcactgagttaatgacctacggga tcccgtaggtcattaactcagtgatgatatagaacggg 
F317L-G TTC → TTG cgttctatatcatcactgagttgatgacctacggg cccgtaggtcatcaactcagtgatgatatagaacg 
F317C TTC → TGC ctatatcatcactgagtgcatgacctacgggaacc ggttcccgtaggtcatgcactcagtgatgatatag 
F317I TTC → ATC ttctatatcatcactgagatcatgacctacgggaacc ggttcccgtaggtcatgatctcagtgatgatatagaa 
F317V TTC → GTC ttctatatcatcactgaggtcatgacctacgggaacc ggttcccgtaggtcatgacctcagtgatgatatagaa 
V299L-T GTG → TTG aaacaccctaacctgttgcagctccttgggg ccccaaggagctgcaacaggttagggtgttt 
V299L-C GTG → CTG aacaccctaacctgctgcagctccttggg cccaaggagctgcagcaggttagggtgtt 
M244V ATG → GTG cgcacggacatcaccgtgaagcacaagctgg ccagcttgtgcttcacggtgatgtccgtgcg 
L248V CTG → GTG atgaagcacaaggtgggcgggggcc ggcccccgcccaccttgtgcttcat 
G250E GGG → GAG acaagctgggcgagggccagtacgg ccgtactggccctcgcccagcttgt 
Q252H-T CAG → CAT ggcgggggccattacggggaggt acctccccgtaatggcccccgcc 
Q252H-C CAG → CAC ggcgggggccactacggggaggt acctccccgtagtggcccccgcc 
T315A ACT → GCT ccccgttctatatcatcgctgagttcatgacctac gtaggtcatgaactcagcgatgatatagaacgggg 
T315I ACT → ATT agcccccgttctatatcatcattgagttcatgacc ggtcatgaactcaatgatgatatagaacgggggct 
M351T ATG → ACG cagatctcgtcagccacggagtacctggaga tctccaggtactccgtggctgacgagatctg 
F359V TTC → GTC gagtacctggagaagaaaaacgtcatccacagagatc gatctctgtggatgacgtttttcttctccaggtactc 
H396P CAT → CCT cacctacacagcccctgctggagccaagt acttggctccagcaggggctgtgtaggtg  
H396R CAT → CGT cacctacacagcccgtgctggagccaagt acttggctccagcacgggctgtgtaggtg 
 
 
Table 4. Primer pairs designed for mutagenesis assays. Indicated are the type of mutation, 
the resulting base exchange and the sequences of fw and rev primers required for mutagenesis 
assays using the QuikChange II Site–Directed Mutagenesis Kit (Stratagene, CA, USA). 
 
3.1.4 Testing for sensitivity, divergence and specificity 
 
To determine the lowest size of mutated cell clones detectable by the LD-PCR 
approach (limit of detection or sensitivity of the assays), dilution series in a 
range of 0% to 100% (0%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 
80%, 90%, and 100%) were established. For this purpose, DNA from mutated 
plasmids was mixed with WT plasmids resulting in a total amount of 10 ng/µl for 
each dilution step. The dilution series for each individual LD-PCR system was 
tested in a minimum of triplicate reactions. The lowest reproducibly detected 
dilution step lacking any cross-reactivity with the WT sequence was regarded as 
the limit of detection.  
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Since mutant and WT ABL1 TK sequences only differ by a single base, cross-
reactions between WT and MUT Lig-oligonucleotide can occur. Thus, data 
calculated directly from the results of capillary electrophoresis were shown not 
to reflect the actual proportions of WT and mutated cell clones. To account for 
this problem resulting from the occurrence of cross-reactivity, calibration curves 
were established by preparing dilution series of quantified plasmids containing 
WT and Mut sequences for each mutation. Standard curves were used to 
convert values measured by LD-PCR into percentages of cells displaying a 
specific mutation, in order to account for the differences between measured and 
true values. A statistical program specifically designed for the present study was 
employed for the evaluation of measurements in CML patients.  
 
To test for possible cross-reactions between different LD-PCR assays for 
adjacent ABL1 TK point mutations, a series of experiments was performed. 
Dilution steps of 5%, 10%, 50% and 100% of plasmids representing the 
potentially cross-reacting LD-PCR system(s) were tested as described above 
and no relevant cross-reactivity was observed (data not shown). 
 
3.1.4.1 Statistical analysis 
 
Statistical evaluation was performed by an external statistician. Initial 
assessment of confidence intervals was based on independent analysis of LD-
PCR detection systems for three different mutations (T315I, E250G, Y253F). 
For each detection system, three dilution series dk were produced at levels x = 
0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,0.95 and 1. For each dilution series, three 
semi-nested PCR approaches were performed. Three independent LD-PCR 
analyses lj(k) were conducted independently, and each LD-PCR assay was 
subjected to two independent measurements by fluorescent capillary 
electrophoresis ai(j(k)). Denoting the measurements with y, the following model 
was applied: ijkkjikjkijk aldxfy ε++++= ))(()()( , where f(x) is a non-linear function, 
the factors dk  , lj(k), and ai(j(k)) are nested, and εijk is the error term. Analysis was 
restricted to polynomial regression, where f(x) is a polynomial of maximal 
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degree four. To assess the effects of the three factors, analysis of covariance 
was performed using SAS PROC GLM (SAS Institute Inc., SAS 9.1.3 Help and 
Documentation, Cary, NC: SAS Institute Inc., 2000-2004). After ensuring that 
neither the dilution series dk nor the fragment analysis ai(j(k)) exert significant 
effects, the average over measurements by fluorescent capillary electrophoresis 
was taken and then the simplified model εβ += ),(xfy  was considered, where 
the term ε contains all random errors due to dilution series and LD-PCR. Based 
on the analysis, the error resulting from dilution series could be regarded as 
negligible compared to the error derived from the LD-PCR. The calibration task 
of specifying x based on measurements y was referred to as inverse regression. 
The computation of confidence intervals of x was performed in Matlab using 
polynomial regression as described [97]. 
 
3.1.4.2 Establishment of calibration curves 
 
Calibration curves were established for the detection and quantification of 21 
point mutations, M244V, L248V, V299L-C/T, G250E, Q252H-C/T, Y253F, 
Y253H, E255K, T315A, T315I, F317C, F317I, F317L-A/G, F317V, M351T, 
F359V, H396P and H396R located in the BCR-ABL1 TK domain. For this task, 
dilution series were generated by mixing MUT- in WT-plasmid DNA as 
described above. 
To evaluate the number of experiments needed for the generation of calibration 
curves of high quality and to determine the parameters of sensitivity, 
divergence, specificity and reproducibility, a training-set including three 
mutations (G230E, Y253F and T315I) was analyzed. For this purpose each, 
three independent dilutions series were prepared for each mutation, which were 
tested by three independent semi-nested PCR amplification reactions. Each 
target was investigated three times using the appropriate LD-PCR assay and 
analyzed twice by capillary electrophoresis. Within this set of experiments, 702 
data points were generated and evaluated by statistical methods as described. 
Results indicated that the LD-PCR itself was the only factor significantly 
influencing the outcome of the analyses.  
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Based on the observations in the training set, it was decided to limit the number 
of experiments for the establishment of calibration curves for the remaining 
point mutations (test set). Thus, one dilution series was used to perform one 
semi-nested PCR, which was analyzed by LD-PCR in triplicates and separated 
by a single run on the capillary electrophoresis instrument. An example of peaks 
obtained after capillary electrophoresis is shown in Figure 12. 
The results were used to prepare calibration curves, a selection of which is 
shown in Figures 13a -13f.  
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Figure 12. Displayed are results for parts of the Y253F plasmid dilution series (0% Mut to 40% 
Mut). LD-PCR products were separated by capillary electrophoresis. The x-axis shows the peak 
heights in rfu (relative fluorescence units), the y-axis shows the PCR products lengths in bp. 
The left peak indicates the WT PCR product, the right peak the MUT PCR product. Due to the 
stuffer sequence within the Lig-MUT oligo, the MUT PCR product is six bp longer. 
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Figure 13a. Calibration curve for G250E. 
 
 
 
 
Figure 13b. Calibration curve for M244V. 
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Figure 13c. Calibration curve for M351T. 
 
 
 
 
Figure 13d. Calibration curve for T315I. 
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Figure 13e. Calibration curve for Y253F. 
 
 
 
Figure 13f. Calibration curve for Y253H. 
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3.1.4.3 Sensitivity, specificity and reproducibility of the LD-PCR assays 
 
Based on the analyses of dilution series, sensitivity, specificity and 
reproducibility were tested for all 21 LD-PCR systems. The lowest reproducibly 
detected dilution step lacking cross-reactivity was defined as the detection limit 
(sensitivity) of the assays. Depending on the level of cross-reactivity with the 
WT sequence, detection limits of 1% (for LD-PCR systems M244V, M351T, 
F317L-A, Q252H-T, F317C, F317V, L248V, T315A, V299L-C, V299L-T, F359V, 
H396P and H396R), and 1-5% (for Y253H, F317L-G, E255K, Q252H-C, F317I, 
T315I, G250E and Y253F) were identified.  
Cross-reactions with the WT sequence, differing by a single base, influenced 
the specificity of the assays. Thus, the expected (i.e. true) and the measured 
values were not concordant. Calibration curves were established, facilitating 
correction of the measured value to determine the true value. The 
implementation of calibration curves as a correction tool was feasible because 
the reproducibility of the assays was high, revealing an inter-assay variability of 
± 2%. Results obtained from calibration curves analyses were the basis for a 
dedicated computer program established by the statistician, which facilitated 
automatic conversion of LD-PCR results to the size of mutant clones. Moreover, 
95% confidence intervals (CI) were calculated and determined to be in a range 
of ± 5%. This implies that consecutive measurements of mutant clones in a 
patient can be regarded as true changes if the 95% CIs do not overlap. Hence, 
the elevation or decrease by 10% can be regarded as a true change in the size 
of mutant clones. 
 
 
Results                                                                                                                   Sandra Preuner 
 68 
3.1.5 Analysis of patient samples 
 
3.1.5.1 Proof of principle experiment 
 
To assess the clinical applicability of the LD-PCR systems, a cohort of 30 
chronic phase CML patients with suboptimal response to imatinib and 7 control 
patients with optimal response to treatment were included in a pilot study. RNA 
extraction and cDNA synthesis were performed as indicated above. Detection of 
BCR-ABL1 point mutation was done by bidirectional sequencing. Seven 
patients revealed four different point mutations including M244V, Y253H, 
G250E and M351T (Table 5). In contrast, none of the control patients showed 
BCR-ABL1 TK point mutations.  
 
 
Patient 
Result Direct 
Sequencing 
Result LD-PCR          
(% MUT) 
1 G250E 100 
2 Y253H 100 
3 G250E 100 
4 M351T 14 
5 M244V 97 
6 G250E 51 
7 M351T 100 
 
 
Table 5. Results of “Proof of principle experiment” for the applicability of LD-PCR. Type 
of mutation detected by sequence analysis in seven CML patients with suboptimal response to 
treatment with imatinib and proportion of mutant clones determined at individual time points by 
LD-PCR and fluorescent capillary electrophoresis are displayed. 
 
 
Moreover, this proof of principle experiment was used to determine the 
applicability of LD-PCR to the monitoring of subclone-specific proliferation 
kinetics. Serial blood specimens obtained from a CML patient under imatinib 
treatment, with a M351T point mutation were analyzed by LD-PCR. LD-PCR 
results were correlated with the BCR-ABL1/ABL1 ratio measured by real-time 
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PCR analysis. As shown in Figure 14, the mutant subclone (solid line) was not 
detectable within the first weeks of imatinib treatment, with the exception of day 
48, when the clone was transiently detected at a level of 6%. After 
approximately one year of treatment, the size of the M351T subclone increased 
to 82%, and within the next two months, to 92% of the BCR-ABL1 expressing 
cells. During the entire observation period, fluctuating BCR-ABL1/ABL1 
expression (dashed line) was detected, with an increase to 100% concomitantly 
with the expansion of the mutated subclone. 
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Figure 14. Proliferation kinetics of a M315I point mutated subclone in a CML patient under 
imatinib treatment.  
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3.1.6 LD-PCR application to the detection/quantification of the V617F 
mutation within the JAK2 gene 
 
The point mutation leading to replacement of the amino acid valine by 
phenylalanine at position 617 in the JAK2 protein is a critical activating genetic 
event in patients with myeloproliferative disorders (MPD). The detection of this 
mutation and quantitative monitoring of cells carrying the underlying nucleotide 
exchange are essential diagnostic tests in the surveillance of patients with 
MPD. In view of the clinical importance, it was of great interest to assess the 
applicability of the LD-PCR technique at this task. 
 
3.1.7 Design of the LD-PCR system for analysis of the V617F mutation 
 
Based on the experience gained from the related work in CML, LD-PCR 
oligonucleotides required for the detection/quantification of the point mutation in 
the JAK2 gene leading to the V617F variant were designed as described above. 
Oligonucleotides were designed in a reverse complementary fashion to display 
a hybridization temperature of 70°C (Table 6)  
 
LD-System Primer     Stuffer    Oligo 
Hybridization-
temperature                   
(C°) 
Lig/Hyb oligo properties 
JAK2     
lengths 
(bp) 
G/C content 
(%) 
TM 
(°C) 
Lig Oligo 
WT 
gggttccctaagggttggactcacaagcatttggttttaaattatggagtatgtg 
70 
36 33 71 
Lig Oligo 
Mut 
gggttccctaagggttggacaacccctcacaagcatttggttttaaattatggagtatgtt  
  
36 31 70 
Hyb Oligo 5´Phos tctgtggagacgagaatattctggttcagtctagattggatcttgctggcac   29 45 71 
 
Table 6. Characteristics of the LD-PCR detection system for JAK2 V617F. 
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3.1.8 Experimental set-up 
 
To pre-amplify the LD-PCR target sequence of interest, a specific PCR reaction 
was established. PCR fw and rev primers were designed using the following 
gene-bank sequence: [>gi|13325062|ref|NM_004972.2| Homo sapiens Janus 
kinase 2 (a protein tyrosine kinase) (JAK2), mRNA] and the PrimerExpress 
software 2.0 (AB). From a list of potential fw and rev primers provided by the 
program, three fw primers (JAK2 fw1 5´ GCAGCAAGTATGATGAGCAAGCT 3`; 
JAK2 fw2 5´ TGAAGCAGCAAGTATGATGAGCA 3´; JAK2 fw3 5´ 
TCAGAGTCTTTCTTTGAAGCAGCA 3´) and one rev primer (JAK2 rev 5´ 
TGCCAACTGTTTAGCAACTTCAAG 3`) were selected and tested for the best 
PCR performance. The PCR reaction included the following reagents: each 400 
nM of each fw and rev primer, 2 mM dNTPs, 0,5 U HotStar® Polymerase 
(Promega), 10 x buffer (Promega) and 50 ng template DNA (100% WT plasmid 
DNA) in a total volume of 25 µl. The PCR reaction was performed according to 
the following cycling protocol: 94°C for 5 min, fol lowed by 30 cycles of 94°C for 
1 min, 60°C for 30 sec. and 72°C for 1 min, and coo ling to 4°C. PCR products 
were analyzed on a 1.5% agarose gel. Based on its superior performance, the 
JAK2 fw1 primer was selected for further experiments.  
Appropriate dilution series of WT and mutant plasmids were generated, and the 
LD-PCR approach was carried out as described. Statistical analysis of the 
sensitivity, specificity and reproducibility were performed. The detection limit of 
the assay was determined to be 1% and the data generated were analyzed by a 
dedicated computer program to convert the measured into true values.  
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3.1.9 Analysis of patient samples 
 
Fifteen patient specimens, either methanol/acetic acid-fixed cells or fresh white 
blood cells from patients suffering from different myeloproliferative disorders 
(including essential thrombocytopenia and myelofibrosis) were analyzed for the 
presence and amount of V617F positive cells according to the protocols 
established. In 12 patients, the V617F mutation could be detected in different 
proportions of the cells analyzed. The results are displayed in Table 7.  
 
Patient 
Result of LD-PCR        
(% Mut) 
Pat 1 15 
Pat 2 95 
Pat 3 93 
Pat 4 45 
Pat 5 0 
Pat 6 6 
Pat 7 41 
Pat 8 0 
Pat 9 0 
Pat 10 46 
Pat 11 13 
Pat 12 57 
Pat 13 60 
Pat 14 31 
Pat 15 23 
 
Table 7. LD-PCR results obtained in 15 patients with suspicion of V617F within the JAK2 gene.   
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3.2 PNA/hybprobe assay 
 
In view of the well established applicability of PNA-based assays to specific 
detection of point mutations, it was of interest to test this approach in 
comparison to the LD-PCR technique in order to assess whether one of these 
methods would provide advantages for diagnostic applications in the clinical 
setting.  
 
3.2.1 Design of Hybprobes and PNA oligonucleotides 
 
The LightCycler Probe Design Software 2.0 was used to design hybprobes 
specifically detecting the T315I point mutation. The proportion of the ABL1 TK 
sequence part containing the AA position 315 was used as a basis for the 
design and the following setting were chosen: LC DNA HP Master; Experiment 
type: mutations; Hybprobes; assign the base to be targeted; select specificity of 
the hybprobes for the WT or the mutated base. Under “primer and probe sets”, 
a list of potential fw and rev primers, anchor- and sensor probes was displayed. 
The final primer and probe set was selected based on the ranking established 
by the software. 
 
PNA oligonucleotide design was done according to several criteria: i) the PNA 
oligonucleotide was designed to be complementary to the WT sequence; ii) it 
had to be located within the sequence flanked by fw and rev primers; iii) the 
location of the point mutation had to be in the middle part of the PNA sequence, 
resulting in the competitive hybridization of anchor or sensor probes with the 
PNA oligonucleotide; iv) the maximum lengths of the PNA oligonucleotide was 
19 bp to provide adequate solubility; v) the melting temperature of the PNA 
oligonucleotide had to be higher than the extension temperature of the 
polymerase to prevent premature displacement  vi) the ABI PNA Probe 
designer (http://www.appliedbiosystems.com/support/pnadesigner.cfm) was 
employed to prevent secondary structure formation.  
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3.2.2 Establishment of the PNA/hybprobe assay 
 
3.2.2.1 Optimization of reaction conditions  
 
To find optimal reaction conditions, a variety of experiments using different 
concentrations of hybprobes, PNA oligonucleotides and control plasmid/patient 
DNA were performed (overview in Table 8).  
 
PNA conc. 
(µM) 
Anchor/Sensor probe conc. 
(µM) 
Plasmid 
conc.(ng) 
Patient DNA conc. 
(ng) 
0,25 0,2 100 50 
0,35 0,32 50 100 
0,45   0,5   
0,55   0,005   
0,65   0,00005   
0,75       
1,25       
 
Table 8. Reaction conditions tested for the establishment of the PNA/hybprobe assay.   
 
Within this first set of experiments, a rough titration of the PNA oligonucleotide 
(0,25 µm; 0,75 µM and 1,25 µM) was performed, while the amounts of fw 
(5´CTGCAGTCATGAAAGAGATCAA 3´)  and rev primers (5´ 
CATGTACAGCAGCACCAC 3´), anchor (5´ LC Red 640-
CTCAATGATGATATAGAACGGGGGCTC-Phosphate) and sensor (5´ 
TCCAGGAGGTTCCCGTAGGTCATG-Fluorescein 3`) probes remained 
constant using standard concentrations of 500 nM and 0,2 µM, respectively, in 
the presence of 5 x Genoptyping Mastermix for LightCycler®480. The 
hybrobe/PNA assay was carried out using a modified hybprobe amplification 
program, adding a PNA annealing step at the corresponding PNA melting 
temperature (70°C): pre-incubation for 10 sec at 95 °C, followed by 30 
amplification cycles with 10 sec at 95°C, 10 sec at  70°C, 10 sec at 60°C and 10 
sec at 72°C. The melting curve was established unde r the following conditions: 
1 min at 95°C followed by 2 min of gradual increase  in temperature from 40°C 
to 95°C, and subsequent cooling to 4°C. 
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The concentration of the template plasmid DNA was 50 ng for analysis of 100% 
WT, T315I, T315A. Results showed that the amplification of the WT plasmid 
DNA could be strongly inhibited by all 3 PNA concentrations tested, in contrast 
to the control experiment lacking any PNA oligonucleotide (Figure 16).   
 
The PNA concentration of 1,25 µM, provided only slightly stronger inhibition of 
WT amplification than that observed at 0,75 µM. The latter concentration was 
therefore favoured in order to save costs. The inhibition by 0,25 µM PNA 
oligonucleotide concentration was weaker in comparison to 0,75 µM. To further 
optimize the PNA oligonucleotide concentration, a fine titration experiment was 
performed covering the range of 0,25 µM and 0,75 µM (0,35 µM, 0,45 µM, 0,55 
µM and 0,65 µM; data not shown). No further improvement could be achieved 
and the optimal concentration for the PNA oligonucleotide was therefore defined 
at 0,75 µM. 
 
To optimize the input of plasmid DNA, different amounts (50 ng, 500 pg, 5 pg, 
50 fg) were tested using 100% WT, T315I and T315A and T315I dilution steps 
(0,01%, 0,1%, 1%, 5% and 10%). Template amounts of 50 ng and 500 pg 
permitted the detection of the 1% dilution step, while this level of sensitivity was 
not achievable with 5 pg and 50 fg template. The dilution steps of 0,01% and 
0,1% could not be detected at any of the template concentrations tested 
indicating that the limit of detection for mutant subclones by the PNA/hybprobe 
assay might be around 1%. Fifty ng of plasmid DNA was the finally selected 
amount of template because it provided slightly higher fluorescence intensity 
than 500 pg template  
In attempts to improve the fluorescence intensity and thus the limit of detection 
of the assay, the concentrations of anchor and sensor probes were increased to 
0,32 µM. The results showed, however, that the sensitivity could not be 
significantly improved.  
Hence the initial experiments indicated that the following reaction conditions are 
optimal: 500 nM each fw and rev primer; 0.2 µM each anchor and sensor probe; 
0.75 µM PNA oligonucleotide and 50 ng plasmid DNA template . 
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3.2.2.2 Testing of sensitivity and specificity 
 
To determine the occurrence of cross-reactions and thus define the specificity 
of the assay, 100% WT, T315I and T315A plasmids were analyzed. Melting 
curve analyses permitted the differentiation between WT, T315I and T315A. 
The strongly inhibited WT clone showed a melting temperature of 55°C, T315A 
of 61°C and T315I of 67°C. The results revealed tha t overlapping melting 
temperatures did not occur and WT and both mutated clones could be 
unambiguously discriminated.  
To define the sensitivity of the hybprobe/PNA assay, 50 ng of the dilution steps 
0%, 0,1% 1%, 5%, and 100% MUT (mutant clone), generated for LD-PCR 
analyses were amplified using the optimized reaction conditions: 0,2 µM of each 
anchor and sensor hybprobes and 0.75 µM PNA oligonucleotide. 
The assay was shown to display a detection limit of 1% mutated cell clones 
(Figure 15).  
 
 
Figure 15. Experimental results of the assessment of sensitivity. The Y-axis shows the relative 
fluorescence intensity (displayed as first derivation) of the melting peaks, and the X-axis the 
melting temperature of the PCR amplicons in °C. The  last dilution step detected was 1%, 
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whereas the 0,1% step showed no amplification distinguishable from the negative control (A. 
bidestillata). 
 
 
Figure 16. PNA/Hybprobe approach without PNA oligonucleotide addition. The Y-axis shows 
the relative fluorescence intensity (displayed as first derivation) of the melting peaks, the X-axis 
the melting temperature of the PCR amplicons in °C.  Amplification of WT, T315A ,and T315I 
plasmid DNA is shown. 
 
 
3.2.2.3 PNA oligonucleotide re-design 
 
The PNA oligonucleotide was designed to overlap and thus interfere both the 
anchor and the sensor hybprobe. Since from the theoretical point of view, this 
design could result in a weaker inhibition of the WT signal, the PNA 
oligonucleotide was re-designed to only overlap with the sensor hybprobe. 
Additionally the PNA oligonucleotide was extended in length to achieve a higher 
hybridization temperature, clearly different from the Hybprobe annealing 
temperature. The newly designed PNA oligonucleotide was tested by applying 
the optimized parameters indicated above. Indeed, a considerably stronger 
inhibition of the WT signal, compared to the original PNA could be achieved 
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(Figure 17). However, the sensitivity of the assay for the detection of T315I 
mutant cells remained at 1%. 
 
 
 
Figure 17. Test results of the newly designed PNA oligonucleotide. The Y-axis shows the 
relative fluorescence intensity (displayed as first derivation) of the melting peaks, the X-axis the 
melting temperature of the PCR amplicons in °C. The  signal for the WT sequence is strongly 
inhibited. The last dilution step detected was 1% T315I point mutated subclone.  
 
 
3.2.2. Analyses of patient samples 
 
To demonstrate the clinical applicability of the T315I PNA/hybprobe approach, 
CML patient samples with known T315I mutation were analyzed. However, 
using the optimal reaction conditions established for plasmid DNA, no results 
could be obtained in the majority of instances. Therefore, further optimization 
steps had to be implemented. This mainly concerned the number of 
amplification cycles, which were increased from 30 to 50, and the input of 
patient DNA, which was increased to 100 ng. Under these conditions, the T315I 
could be detected in all patients analyzed (Figure 18). 
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Figure 18. Analysis of CML patients with known T315I mutation. The Y-axis shows the relative 
fluorescence intensity (displayed as first derivation) of the melting peaks, the X-axis the melting 
temperature of the PCR amplicons in °C. Patient sam ples were analyzed in duplicates clearly 
indicating a T315I mutation by revealing a melting temperature of 67°C. 
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4 Discussion 
 
Point mutations within the ABL1 TK domain are the most frequent cause of 
imatinib failure in CML [44], and can result in disease progression. This finding 
may necessitate the change of treatment to another TKI, such as nilotinib or 
dasatinib or, in some instances, the implementation of allogeneic stem cell 
transplantation.  
Accordingly, the ELN organization recommends to search for point mutations 
upon diagnosis of suboptimal response or treatment failure [35]. Bidirectional 
sequencing of the entire BCR-ABL1 TK domain currently represents the method 
of choice offering a sensitivity of about 20%. This detection limit could be 
inadequate in the clinical setting because it may result in delayed detection of 
point mutations and consequently late diagnosis of impending relapse.  
More sensitive methods are available, e.g. HPLC (high pressure liquid 
chromatography), described to provide a sensitivity of 0,1-15% [79-81]. 
However, HPLC is a rather laborious procedure requiring appropriate, 
expensive equipment. Another technique, ASO-PCR, displays extraordinarily 
high levels of sensitivity, but the applicability of this technique in the clinical 
setting is questionable because the clinical relevance of very small mutant cells 
clones appears to be very low [83]. 
However, even the presence of point mutated subclones at higher levels is not 
necessarily predictive for the onset of clinical resistance. Results obtained from 
analyses of several patient samples indicated that mutant clones can either 
disappear spontaneously, possibly attributable to the restricted self-renewal 
capacity of such clones, or they can persist on low levels without further clonal 
evolution, or clones can increase in size and ultimately confer resistance to 
treatment [95].  
The aim of this study was therefore the development of methodological 
approaches to the detection of point mutated subclones in a clinically relevant 
range of sensitivity, based on the use of standard equipment available in most 
molecular laboratories. Moreover, the possibility to determine the size of 
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mutated subclones permitting the monitoring of proliferation kinetics was 
envisaged.  
In their paper, Schouten et al [87] presented the power of the MLPA technology 
for the detection of multiple point mutations and SNPs. This provided the basis 
for the idea to develop a new methodology, based on the principle of this 
technique.  
The newly established ligation-dependent PCR technique (LD-PCR) was 
designed to target only one point mutation per reaction, and therefore contains 
only few oligonucleotides including one specific for the WT sequence, and one 
specific for the point-mutated sequence (6 bp longer) which bind to their target 
sequences in a competitive manner (ligation oligonucleotides). A third, the so-
called hybridization oligonucleotide, which binds immediately 3´ to the point 
mutation, is subsequently ligated to its adjacent counterpart. The inclusion of a 
ligation step at the site of mutation is an important feature providing increased 
specificity in comparison to techniques such as ASO-PCR, which rely only on 
sequence-specific hybridization of primers. Moreover, the possibility of using 
universal primers for PCR amplification of the ligated template molecules 
provides the ability to analyze different point mutations within one workflow, 
which is both time-saving and convenient. 
An important modification compared to the MLPA approach was the reduction 
of the hybridization time from 16 hours to one minute only. This modification 
was introduced to due several reasons: i) the LD-PCR assay includes only three 
oligonucleotides instead of up to 80, and long hybridization times are therefore 
not required ii) extension of the hybridization time affects the ratio of WT- and 
MUT- specific signals (data not shown). This might be mainly attributable to the 
increased occurrence of non-specific hybridization of the ligation 
oligonucleotides, as described (www.mlpa.com). Hence, regardless of the high 
specificity provided by the ligase enzyme, cross-reactivity of the ligation 
oligonucleotides with the WT- and MUT- sequence occurs, and this seems to be 
intensified by long hybridization times.  
With regard to the design of LD-PCR oligonucleotides, the rules published for 
MLPA were followed whenever possible, but this aim was not achievable in all 
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instances. The major challenge was the fixed position of the point mutation 
within the BCR-ABL1 TK sequence. This is an important difference to MLPA 
approaches, which target specific genes, but not specific bases. Difficulties 
were observed in the design of tests for mutations within the p-loop of the BCR-
ABL1 TK domain. This was mainly attributable to the very high C/G content 
within this region, which required the design of short oligonucleotides, far below 
the lengths of 21 nt recommended by the MLPA guidelines. Shorter 
oligonucleotides, however, show a higher frequency to hybridize to similar but 
incompletely homologous nucleotide sequences. To overcome this difficulty, 
LD-PCR systems were designed to bind at a higher hybridization temperature of 
75°C. 
To set up the new technique and to test the designed LD-PCR oligonucleotides, 
calibration and positive control samples had to be implemented. Synthetically 
produced oligonucleotide template sequences were first used to determine the 
functionality of several LD-PCR oligonucleotides. These synthetic templates 
contained the oligonucleotide sequences targeted within the patient cDNA, and 
dilution series of MUT and WT sequence were generated across a range from 
0%-100% mutated sequence mixed in WT sequence (0%, 5%, 10% 20%, 30%, 
40%, 50%, 60%, 70%, 80% 90%, 100%). This approach was subsequently 
abandoned, because it does not adequately reflect the physiological situation 
owing to the lack of background cDNA present in the patient samples. A test 
system, more closely mimicking patient cDNA might be a cell line. A BaF3 
murine cell line carrying the BCR-ABL1 rearrangement was generated by a 
group in Oregon [98], and this cell line is also available with a variety of BCR-
ABL1 TK domain point mutations. However, the BaF3 cell line did not appear to 
be adequate as a reference system based on the following considerations: 
a) only a limited number of point mutated Baf3 cell lines were available either 
commercially, or to a small extent, within scientific collaborations, and the costs 
of the commercial products were prohibitive. b) the generation of different point 
mutated BaF3 cell lines, for all mutations (≥ 21) required would have been too 
laborious and time-consuming. Based on these considerations, it was decided 
to generate plasmids carrying the BCR-ABL1 sequence of interest and to 
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introduce the required point mutations via mutagenesis assays. This procedure 
seemed to be a straight-forward concept. Plasmid-based positive control 
samples were generated for 21 point mutations frequently occurring within the 
BCR-ABL1 TK domain, and for the V617F mutation within the JAK2 gene. For 
each LD-PCR system, plasmid dilution series were generated as indicated 
above and used to validate the assays with regard to sensitivity, specificity and 
reproducibility.  
The sensitivity of the LD-PCR assays was demonstrated to be in a range of 1-
5%. This was mainly attributable to some degree of cross-reactivity of the MUT 
Lig oligonucleotide with the WT sequence and vice versa, as already described. 
It needs to be considered, however, that capillary electrophoresis which had 
been selected as the detection method, cannot provide a much better sensitivity 
than 1%. This results from the fact that the peak heights of PCR amplicons can 
be detected only up to a maximum of about 6 000 rfu (relative fluorescence 
units) and a minimum of 50 rfu. Since LD-PCR is a comparative assay between 
WT and MUT sequences, the detectable signal intensities indicated maximally 
permit the analysis of peak ratios of 6 000 : 50, which corresponds to 0.8%. The 
assay reproducibility of the assay was demonstrated to be in a range of ± 2%. 
However, this does not reflect the intrinsic variability in the clinical setting but 
only describes the robustness of the assays. Thus, the most important issue 
was to determine which results reflect true changes in the size of mutant clones 
when measuring consecutive patient samples. Based on the statistical 
calculations, a true change was determined to be in a range of ± 5%, based on 
the lack of overlap between 95% confidence intervals. The size of the mutant 
clones and the corresponding 95% confidence intervals can be easily calculated 
by implementing the computer program, generated specifically for this 
technique.  
Based on the accurate evaluation of the LD-PCR method, the technique was 
tested on patient samples obtained from CML patients with suboptimal 
response to imatinib treatment in a proof-of-principle study. Analyses in 30 
patients demonstrated that the LD-PCR system can reliably detect the mutant 
subclones and their size can be calculated using a dedicated computer 
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program. Moreover, it could be demonstrated that the proliferation kinetics of a 
mutant subclone can be documented by the LD-PCR approach. Since these 
observations were based on a preliminary set of experiments, the benefit of the 
LD-PCR approach in the clinical setting had to be confirmed in a lager cohort of 
patients. The first results of the study indicate that the percentage of BCR-ABL1 
positive cells in the samples tested might be an additional parameter influencing 
the accuracy of the LD-PCR approach. Further testing within extensive clinical 
studies is ongoing.  
A further aim of this diploma thesis was to proof whether the LD-PCR technique 
developed could be adapted to sensitive detection/quantification of point 
mutations in genes other than BCR-ABL1. This was demonstrated by using the 
clinically important point mutation V617F in the JAK2 gene in patients suffering 
from different myeloproliferative disorders. The detection of this point mutation 
was shown to be of clinical relevance because it is associated with a 
constitutive tyrosine kinase activity contributing to malignant transformation [99]. 
The LD-PCR assay detecting/quantifying the JAK2 V617F mutation was 
established according to the procedure described for the BCR-ABL1 point 
mutations. To demonstrate that this method provides reliable results, patients 
who tested positive for this mutation at the University of Innsbruck by a different 
qualitative method were re-evaluated using the LD-PCR technique. Identical 
results were obtained by both methods, thus confirming the clinical applicability 
of the LD-PCR method for the detection of the JAK2 V617F mutation. Moreover, 
the available results indicated, that the LD-PCR technique can be adapted to 
detection/quantification of virtually any other point mutation of interest, provided 
that the target region contains a DNA/cDNA sequence permitting the design of 
LD-PCR oligonucleotides.  
As potential alternative to the LD-PCR method, a technique based on specific 
amplification of the mutant subclone and simultaneous repression of WT 
amplification was established. This method combined the use hybprobes, 
specifically amplifying the point mutated sequence with PNA clamping of the 
WT sequence. This assay was expected to permit more sensitive qualitative 
detection of the clinically important T315I point mutation. However, despite the 
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efforts to optimize the PNA/hybprobe assay for maximum sensitivity, the lowest 
achievable limit of detection for the T315I point mutated subclones was 1%, 
which is not superior to the LD-PCR approach. Since the LD-PCR technique 
also permits quantitative assessment of the mutant subclones, it remains the 
method of choice in our hands. If in specific instances a higher level of 
sensitivity is desired, ASO-PCR can be employed. It is currently not clear, 
however, whether the detection if mutant subclones at a higher level of 
sensitivity is of potential clinical relevance. It can be expected that clinical 
implementation of the LD-PCR technique in CML and other disease entities will 
permit early assessment of impending resistance to treatment as a basis for 
timely and appropriate modification of therapy. 
 
 
 
 
Concluding remarks 
The description of the LD-PCR technique and its application to the detection 
and quantification of point mutations within the BCR-ABL1 TK domain was 
recently published in Leukemia [100]. 
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LETTER TO THE EDITOR
Quantitative monitoring of cell clones carrying point mutations in the BCR–ABL tyrosine
kinase domain by ligation-dependent polymerase chain reaction (LD–PCR)
Leukemia advance online publication, 24 April 2008;
doi:10.1038/leu.2008.97
Tyrosine kinase (TK) inhibitors directed against the BCR–ABL TK
domain have become the standard of treatment in patients with
chronic myeloid leukemia (CML). In a proportion of patients,
however, resistance to TK inhibitors may occur, which, in the
case of imatinib, has been associated with point mutations
within the ABL TK domain in 40–90% of instances, depending
on the CML phase, the methodology of detection and the
definition of resistance.1 Mutations conferring resistance fre-
quently occur at the ATP-binding site (P-loop) or at other sites
directly affecting drug binding or conformation of the kinase
(activation loop, catalytic domain). The level of resistance to
individual TK inhibitors may vary from slightly reduced
sensitivity to total insensitivity. In patients receiving treatment
with imatinib, mutations conferring only moderately impaired
sensitivity may be approached by increasing the dose, while the
presence of mutations associated with a high level of resistance
provides an indication for switching treatment to second
generation compounds, such as dasatinib or nilotinib.2 Point
mutations reported to confer high levels of resistance to imatinib
include for example, Y253F/H, E255K/V, T315I, or H396P/R.2
Dasatinib and nilotinib were shown to be instrumental against
most of these mutations,3 but the AA position 315 (-T315I)
remains problematic because none of the currently approved TK
inhibitors are effective in this instance.4 Moreover, recent data
indicate that a range of specific mutations other than the T315I
may occur before and during treatment with dasatinib (V299L,
T315A, F317I/S/V, F317L) or nilotinib (Y253H, E255V, F359C).5
These observations underscore the importance of monitoring
patients on treatment with TK inhibitors for the presence of
mutations. A number of studies in CML patients report on the
occurrence of mutations in the entire BCR–ABL TK domain.
Recent studies in patients treated with imatinib indicate that
E250K, Y253F, E255K, T315I, M351T and F359V account for
60–70% of all mutations. Mutations located within the P-loop
appear to be most frequent and are suggested to correlate with
poor outcome.6 A number of methods have been employed to
detect mutant clones including, for example, PCR amplification
coupled with direct sequencing of the BCR–ABL TK domain,
high-performance liquid chromatography, the SEQUENOM
MassARRAY system, or allele-specific oligonucleotide-PCR
amplification. These techniques display different detection
limits for the identification of mutant clones ranging from
0.01–30%. Detection of a mutation within the ABL TK domain
does not necessarily imply impending onset of clinically
resistant disease, particularly if the size of a mutant clone is
small.7 Mutant clones have been reported to disappear
spontaneously which may, at least in part, be attributable to
the occurrence of mutations in cells with restricted proliferative
capacity.8,9 Qualitative methods for mutational analysis may
therefore have limited potential to reliably assess the risk of
clinically resistant disease, especially if mutant clones present at
very low levels are detected.8 It is currently a matter of
discussion whether the detection of small mutant BCR–ABL
clones, for example, below the level of 1%, is clinically useful.
The clinical benefit of sensitive techniques for mutational
analysis could be increased if the size of mutant clones could
be monitored, to facilitate timely detection of clonally expand-
ing mutant cells during treatment.8 Current approaches to
assessing the size of mutant clones include for example,
pyrosequencing,9 SEQUENOM MassARRAY analysis,10 or the
polymerase colony assay.11 These techniques, however, have
limitations with regard to broad application in clinical diagnosis,
such as the requirement of very expensive equipment,10 rather
complex and laborious design,11 or the apparent inability to
quantify mutant clones in the range below 20%.9 We have
therefore established a relatively simple method facilitating
quantitative analysis of single nucleotide polymorphisms. The
technique is based on ligation-dependent competitive PCR
(LD–PCR) and represents a modification of the MLPA technol-
ogy.12 The LD–PCR technique presented displays a detection
limit for BCR–ABL TK mutations in a range of apparent clinical
relevance, and permits accurate quantitative analysis of mutant
clones. In a pilot study, we demonstrate that the technique can
be readily applied to the detection and monitoring of clones
exhibiting specific mutations within the BCR–ABL TK domain in
patients with CML.
The panel of quantification assays presented covers 18
different mutations including all important base substitutions
located in the P-loop of the tyrosine kinase domain, and other
mutations known to confer a high level of resistance to imatinib,
dasatinib and nilotinib (Table 1). The current panel of LD–PCR
assays permits detection and quantitative monitoring of the
following mutations: M244V, L248V, V299L-C, V299L-T,
G250E, Q252H-C, Q252H-T, Y253F, Y253H, E255K, T315A,
T315I, F317C, F317I, F317L-A, F317L-G, F317V and M351T
(Table 1).
The probes for individual LD–PCR assays including the
ligation (Lig) and hybridization (Hyb) oligonucleotides were
designed according to the criteria established for MLPA analysis,
as specified by MRC Holland (www.mpla.com). Lig specifies the
probes whose 30 terminal bases hybridize to the nucleotide of
interest, and Hyb indicates the adjacent probe (Figure 1). The
Hyb probe is phosphorylated at the 50end as a prerequisite for
the ligation step. The Lig probes for the wild-type (WT) and the
mutant (MUT) sequences display different nucleotides at their 30
terminal positions. Moreover, the Lig-MUT probes contain an
additional ‘stuffer-sequence’ located between the hybridization
sequence and the primer-binding site. The stuffer-sequence is a
stretch of six non-homologous nucleotides which render the
mutation-specific PCR product longer, and thus, readily
distinguishable from the wild-type PCR product by capillary
electrophoresis (Figure 1). The sequences of the Lig and the Hyb
oligonucleotide probes were controlled for the possible forma-
tion of secondary structures under conditions close to the
hybridization temperature, using a program freely available
online: http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/
dna-form1.cgi.
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Table 1 LD–PCR detection systems for 18 mutations in the BCR–ABL TK domain
LD-system Primer tag sequence Stuffer sequence Target hybridization sequence Hybridization temperature (C1)
M244V
Lig Oligo WT gggttccctaagggttggagaacgcacggacatcacca 70
Lig Oligo Mut gggttccctaagggttggatgacctgaacgcacggacatcaccg
Hyb Oligo 50Phos tgaagcacaagctgggcggtctagattggatcttgctggcac
L248V
Lig Oligo WT gggttccctaagggttggaggacatcaccatgaagcacaagc 70
Lig Oligo Mut gggttccctaagggttggataatctggacatcaccatgaagcacaagg
Hyb Oligo 50Phos tgggcgggggccagttctagattggatcttgctggcac
V299 L-C
Lig Oligo WT gggttccctaagggttggacatgaaagagatcaaacaccctaacctgg 70
Lig Oligo Mut gggttccctaagggttggagttgtgcatgaaagagatcaaacaccctaacctgc
Hyb Oligo 50Phos tgcagctccttgggtctgtctagattggatcttgctggcac
V299 L-T
Lig Oligo WT gggttccctaagggttggacatgaaagagatcaaacaccctaacctgg 70
Lig Oligo Mut gggttccctaagggttggagttgtgcatgaaagagatcaaacaccctaacctgt
Hyb Oligo 50Phos tgcagctccttgggtctgtctagattggatcttgctggcac
G250E
Lig Oligo WT gggttccctaagggttggatgaagcacaagctgggcgg 70
Lig Oligo Mut gggttccctaagggttggagtgttgtgaagcacaagctgggcga
Hyb Oligo 50Phos gggccagtacggggaggtctagattggatcttgctggcac
Q252H-Ca
Lig Oligo WT gggttccctaagggttggagccctcgtacacctccccgtac 75
Lig Oligo Mut gggttccctaagggttggatacagagccctcgtacacctccccgtag
Hyb Oligo 50Phos tggcccccgcccagctttctagattggatcttgctggcac
Q252H-Ta
Lig Oligo WT gggttccctaagggttggagccctcgtacacctccccgtac 75
Lig Oligo Mut gggttccctaagggttggatacagagccctcgtacacctccccgtaa
Hyb Oligo 50Phos tggcccccgcccagctttctagattggatcttgctggcac
Y253F
Lig Oligo WT gggttccctaagggttggagctgggcgggggccagta 75
Lig Oligo Mut gggttcccgaagggttggatagtccgctgggcgggggccagtt
Hyb Oligo 50Phos cggggaggtgtacgagggcgtctagattggatcttgctggcac
Y253H
Lig Oligo WT gggttccctaagggttggactgggcgggggccagt 75
Lig Oligo Mut gggttccctaagggttggatgtggtctgggcgggggccagc
Hyb Oligo 50Phos acggggaggtgtacgagggcgtctagattggatcttgctggcac
E255K
Lig Oligo WT gggttccctaagggttggacgggggccagtacgggg 75
Lig Oligo Mut gggttccctaagggttggattcaatcgggggccagtacggga
Hyb Oligo 5´Phos aggtgtacgagggcgtgtggaagtctagattggatcttgctggcac
T315A
Lig Oligo WT gggttccctaagggttggaggagcccccgttctatatcatca 70
Lig Oligo Mut gggttccctaagggttggatcttatggagcccccgttctatatcatcg
Hyb Oligo 50Phos ctgagttcatgacctacgggaacctctctagattggatcttgctggcac
T315I
Lig Oligo WT gggttccctaagggttggaggagcccccgttctatatcatcac 70
Lig Oligo Mut gggttccctaagggttggatcatttggagcccccgttctatatcatcat
Hyb Oligo 50Phos tgagttcatgacctacgggaacctctctagattggatcttgctggcac
F317-C
Lig Oligo WT gggttccctaagggttggacccccgttctatatcatcactgagtt 70
Lig Oligo Mut gggttccctaagggttggattatctcccccgttctatatcatcactgagtg
Hyb Oligo 50Phos catgacctacgggaacctcctgtctagattggatcttgctggcac
F317-I
Lig Oligo WT gggttccctaagggttggagcccccgttctatatcatcactgagt 70
Lig Oligo Mut gggttccctaagggttggattattggcccccgttctatatcatcactgaga
Hyb Oligo 50Phos tcatgacctacgggaacctcctgtctagattggatcttgctggcac
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To obtain positive controls for specific mutations in the BCR–
ABL TK domain and to establish calibration curves for
quantitative analysis, plasmids containing the point mutations
of interest were generated. A BCR–ABL TK domain fragment of
about 1 kb was amplified and cloned into a pGEMt vector
(Promega, Mannheim, Germany). Presence of the wild-type
BCR–ABL sequence was confirmed by direct sequencing in both
directions. This plasmid served as a basis for specific mutagen-
esis within the ABL TK domain using the QuikChange II Site–
Directed Mutagenesis Kit (Stratagene, CA, USA). Mixtures of
wild-type plasmids and mutant plasmids were used to generate
dilution series including the following dilution steps: 0, 1, 5, 10,
20, 30, 40, 50, 60, 70, 80, 90 and 100%. Individual dilution
series were analyzed in triplicates as a basis for the establish-
ment of standard curves. An exemplary standard curve is shown
in Figure 2. The standard curves were used to convert the values
measured by LD–PCR to percentages of cells displaying a
Table 1 (Continued )
LD-system Primer tag sequence Stuffer sequence Target hybridization sequence Hybridization temperature (C1)
F317 L-A
Lig Oligo WT gggttccctaagggttggagcccccgttctatatcatcactgagttc 70
Lig Oligo Mut gggttccctaagggttggacttatcgcccccgttctatatcatcactgagtta
Hyb Oligo 50Phos atgacctacgggaacctcctggatctagattggatcttgctggcac
F317 L-G
Lig Oligo WT gggttccctaagggttggacccccgttctatatcatcactgagttc 70
Lig Oligo Mut gggttccctaagggttggacttatccccccgttctatatcatcactgagttg
Hyb Oligo 50Phos atgacctacgggaacctcctggatctagattggatcttgctggcac
F317-V
Lig Oligo WT gggttccctaagggttggagcccccgttctatatcatcactgagt 70
Lig Oligo Mut gggttccctaagggttggattattggcccccgttctatatcatcactgagg
Hyb Oligo 50Phos tcatgacctacgggaacctcctgtctagattggatcttgctggcac
M351T
Lig Oligo WT gggttccctaagggttggaccactcagatctcgtcagccat 70
Lig Oligo Mut gggttccctaagggttggagatgttccactcagatctcgtcagccac
Hyb Oligo 50Phos ggagtacctggagaagaaaaacttcatcctctagattggatcttgctggcac
aLD-system designed in a reverse complementary fashion.
Figure 1 LD–PCR assay for the detection and quantification of wild-
type (WT) and point-mutated (MUT) sequences. The principle of
LD–PCR is a modification of the MLPA technology.12 The LD–PCR
reaction contains three different probes: (1) The wild-type ligation
probe (Lig-WT) contains a section complementary to the WT target
sequence (b) and a tag sequence for the forward primer (a). (2) The
ligation probe for the mutant sequence (Lig-MUT) (bn) differs from the
Lig-WT probe by a nucleotide at the 30 terminal position complemen-
tary to a specific point mutation. This probe carries the same tag
sequence (a) for the forward primer, but contains an additional stuffer
sequence of six non-homologous nucleotides (c). (3) The common
hybridization (Hyb) probe contains a section complementary to its
target sequence directly adjacent to that of the ligation probes (d) and a
tag sequence for the reverse primer (e). Upon specific hybridization to
the target sequence, the probes are fused under conditions described
in the text, permitting the ligation only in the presence of perfect
match to the target sequence. In a subsequent step, the ligated probes
are amplified competitively in a PCR reaction with a single set of
primers binding to the tag sequences (aþ e). Owing to the difference
in length between the WT- and MUT-derived products, the amplicons
can be readily separated and quantified by fluorescent capillary
electrophoresis.
Figure 2 Calibration curve for LD–PCR analysis. An exemplary
standard curve (mutation M351T) for quantitative analysis by LD–PCR
and fluorescent capillary electrophoresis showing the relation between
measured values (y-axis) and true values (x-axis) is displayed. On the
basis of individual standard curves, a computer program permitting
calculation of the size of mutant clones from measured values was
established for all mutations included in the current panel.
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specific mutation, to account for the differences between
measured and true values. A statistical program specifically
designed for the present study was employed for the evaluation
of measurements in CML patients. Initial statistical evaluation
was based on independent analysis of LD–PCR detection
systems for three different mutations (T315I, E250G, Y253F).
For each detection system, three dilution series dk were
produced at levels x¼ 0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,
0.95, 0.99 and 1. For each dilution series, three LD–PCR
analyses lj(k) were conducted independently and each LD–PCR
assay was subjected to two independent measurements by
fluorescent capillary electrophoresis ai(j(k)). Denoting the mea-
surements with y, the following model was applied:
yijk¼ f(x)þ dkþ lj(k)þ ai(j(k))þ eijk, where f(x) is a non-linear
function, the factors dk, lj(k) and ai(j(k)) are nested, and eijk is the
error term. Analysis was restricted to polynomial regression,
where f(x) is a polynomial of maximal degree four. To assess the
influence of factors possibly affecting quantitative measure-
ments, we performed analysis of covariance using SAS PROC
GLM (SAS Institute Inc., SAS 9.1.3 Help and Documentation,
Cary, NC, USA: SAS Institute Inc., 2000–2004). After ensuring
that neither the dilution series dk nor the fragment analysis ai(j(k))
exert significant effects, we took the average over measurements
by fluorescent capillary electrophoresis and then considered the
simplified model y¼ f(x,b)þ e, where the term e contains all
random errors due to dilution series and LD–PCR. Based on our
analysis, the error resulting from dilution series can be regarded
as negligible compared to the error derived from the LD–PCR.
The computation of confidence intervals of x was performed in
Matlab using polynomial regression as described.13 Biostatis-
tical calculation of a total of 648 data points generated for the
three mutations indicated, identified the LD–PCR itself as the
only statistically relevant variable affecting quantitative analysis.
Based on the evaluation of this model, the standards for
quantitative analysis of all other mutations were established
according to a statistical design based on the remaining variable
determined as relevant. Hence, for every other mutation, 36
data points were collected to establish standards for quantifica-
tion.
The LD–PCR reactions were performed using the thermo-
cycler AB-9600 (Applied Biosystems(AB), Foster City, USA). For
LD–PCR, the following reaction components were mixed on ice:
0.5 ml probe mix (0.8 ml from 1mM concentrations of each Lig-
WT probe, Lig-MUT probe and Hyb probe in 200ml TE buffer),
1.5 ml of MLPA buffer (MRC Holland, Amsterdam, The Nether-
lands) and 50 ng of the BCR–ABL PCR product (determined by
photometric measurement). The BCR–ABL products were
derived from patient specimens (see below) or from calibration
plasmid samples generated by one or two rounds of PCR
amplification.14 To prevent formation of secondary structures
within the target or probe sequences and self-hybridization of
the probes, which might affect the efficiency of the assay, the
reactions were subjected to a hot-start at 98 1C for 5 min. For
specific binding of the Lig and Hyb probes, the reaction was
cooled down to the appropriate hybridization temperature
(Table 1). In contrast to the original MLPA technology, the
hybridization time of the LD–PCR was shortened from 16 hours
to one minute. This change allowed rapid processing and
accurate quantification of mutated cell clones in patient
samples, while the sensitivity of detection remained unaffected.
Subsequently, the reactions were placed at 54 1C for the
addition of ligation reagents: 32 ml of ligation components
including 3ml Ligase-65 buffer A, 3 ml Ligase-65 buffer B, 1ml
Ligase 65 (all MRC Holland) and 25ml water were added to the
reaction. The ligase reactions were performed for 15 min at
54 1C, followed by inactivation of the enzyme for 5 min at 98 1C
and cooling of the samples to 4 1C. Ten ml of this reaction were
mixed with 4ml 10 SALSA PCR buffer (MRC Holland) and
26ml sterile water. After heating to 60 1C to prevent non-specific
primer annealing, the reaction was supplemented with 10 ml of
the PCR-mix containing 2ml FAM-labelled SALSA PCR primers,
2ml SALSA enzyme dilution buffer, 0.5 ml SALSA polymerase (all
MRC Holland) and 5.5ml sterile water. Subsequently, the
appropriate amplification program was performed, as de-
scribed.12 The possible occurrence of false-positive LD–PCR
results was controlled (and successfully excluded) by testing of
multiple BCR–ABL products lacking mutations in the ABL TK
domain.
Quantitative analysis was performed on the ABI PRISM 3100-
Avant Genetic Analyzer (AB). The PCR product obtained from
the LD–PCR reaction was diluted with sterile water at 1:50, and
1ml of the dilution was mixed with 0.3ml GeneScan-500 ROX
Size Standard (AB) and 9 ml Hi-Di Formamide (AB). Denatura-
tion was performed at 94 1C for 3 min, and the reaction was
subsequently cooled to 4 1C. The sample was injected into a
36 cm capillary column containing the high performance
polymer POP-4 (AB) (10 s injection time, 1 kV injection voltage
and 15 kV electrophoresis voltage).
Results were analyzed using the ABI PRISM GeneScan
Analysis software 3.7 (AB). The PCR amplicons of the WT and
MUT products differed in length by 6 bp. Peak heights of the WT
and the MUT products were determined, and the ratio
calculated by the following formula: % MUT¼ (peak height of
MUT product/
P
peak heights of MUTþWT products) 100.
For each mutation, calibration curves were established by
preparing dilution series of quantified plasmids containing WT
and MUT sequences, as indicated above.
All LD–PCR systems established were tested for the limits of
detection and quantitative accuracy by using the appropriate
plasmid dilution series. For several LD–PCR detection systems,
the lowest dilution step analyzed (1%) could be reproducibly
detected and clearly differentiated from the WT sample.
However, as indicated by initial testing, reliable distinction
between WT and MUT targets at levels below 5% has been
difficult for some of the mutations included in the current panel,
because of the presence of cross-reactivity inherent in individual
detection systems. The observation of cross-reactivity was
apparently related to the nucleotide composition at and near
the mutant site. For example, mutations representing a G/C
substitution tended to show a higher potential for non-specific
binding to the target sequence than other non-matching bases.
In some instances, problems associated with the target sequence
could be overcome by designing LD–PCR systems targeting
the opposite DNA strand, as performed for example, for the
mutations Q252H-C and Q252H-T (Table 1). In practice, most
detection systems lacking cross-reactivity actually reach a
detection limit of 1%, while the assays displaying the highest
levels of cross-reactivity observed only permit reliable identifi-
cation of mutant cells at levels ofX5%. Hence, the overall limit
of detection for the mutations included in the study can be
regarded as being in the range between 1–5%. The detection
assays are highly reproducible, with an s.d. of ±2%. The
confidence intervals (95% CI) of quantitative analysis were
calculated on the basis of serial testing of plasmid standards (see
above) and were shown to be in a range of ±5%. We propose
that two subsequent measurements of mutant clones in a
patient, indicating an increasing or decreasing clone size, may
be regarded as a true change if the confidence intervals of
the measured values do not overlap. The application of
this extremely stringent criterion should prevent the
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misinterpretation of variability inherent in the technique.
According to this restriction and the confidence intervals
calculated for individual LD–PCR detection systems, it is
possible to consider elevations or decreases by 10% as true
changes in the size of mutant clones. A computer program based
on an algorithm for the calculation of confidence intervals for all
LD–PCR detection systems has been established. The program
permits automated quantitative assessment of mutant clones on
the basis of values measured by LD–PCR. The implementation of
this tool greatly facilitates the analysis of clinical specimens. The
program is available upon request (Sandra.Preuner@ccri.at).
After careful standardization of all LD–PCR assays using
appropriate plasmid constructs, applicability of the technique in
the clinical setting was assessed in a pilot study. Peripheral
blood specimens derived from 30 CML patients with suboptimal
response and seven control patients with adequate response to
treatment with imatinib were tested. All patients studied were
initially screened for the presence of mutations in the entire TK
domain by direct bidirectional sequencing of appropriate PCR
products, as described.14 The results served as a basis for
subsequent quantitative analysis by LD–PCR. Seven patients
with suboptimal response to imatinib revealed four different
mutations including M244V, Y253H, G250E and M351T
(Table 2). Other specimens analyzed had no evidence of
mutations in the TK domain at the sensitivity level of the
sequencing method. LD–PCR analysis confirmed the findings
and facilitated assessment of the proportion of mutant cells in
peripheral blood specimens (Table 2). To determine the
applicability of LD–PCR analysis to the monitoring of the
proliferation kinetics of mutant clones, six consecutive periph-
eral blood samples of a CML patient carrying a M351T mutation
were analyzed. In this proof of principle experiment, serial LD–
PCR analysis revealed expansion of the mutant clone during the
course of treatment (Figure 3).
It should be pointed out that the LD–PCR method was not
designed for broad mutational screening. The technique is
appropriate for rapid search for a limited number of specific
mutations of interest, and for quantitative monitoring of cell
clones carrying one or more known mutations. It appears that
the method presented may be particularly useful in the following
clinical circumstances:
(a) In the screening for individual mutations of interest. For
example, in patients resistant to imatinib, where the
presence of a particular mutation (for example, the T315I),
should be excluded prior to switching to a second
generation inhibitor.
(b) In the screening for a limited number of specific mutations
in patients treated with a second generation TK inhibitor, in
whom the spectrum of relevant mutations appears to be
restricted.
(c) In the quantitative surveillance of the size of mutant clones
during treatment with any TK inhibitor in patients in whom
the presence of a mutation had been detected by other
approaches (for example, sequencing). The LD–PCR would
then allow the monitoring of the response of individual
mutant clones to current treatment.
The results of the pilot study performed indicate that the LD–
PCR technique presented has the potential to be instrumental in
the clinical setting. The detection assays are robust and provide
rapid quantitative assessment of mutant clones. The current LD–
PCR detection panel covering 18 common mutations can be
easily extended to any other mutation of interest. Prospective
testing of the LD–PCR technique is required to assess the
possible benefit of molecular monitoring of mutant clones in the
clinical management of CML patients.
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